var title_f29_8_29824="SEER surv intrahep cholang";
var content_f29_8_29824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Stratification of survival for 647 patients with confirmed intrahepatic cholangiocarcinoma based on new T category classification using SEER registry data",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T1: solitary tumor without vascular invasion; T2: solitary tumor with vascular invasion or multiple tumors; T3: tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion.",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29824=[""].join("\n");
var outline_f29_8_29824=null;
var title_f29_8_29825="Patient information: Cerebral palsy (The Basics)";
var content_f29_8_29825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82901\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/9/41115\">",
"         Cerebral palsy symptoms at different ages",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cerebral palsy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cerebral-palsy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H22197804\">",
"      <span class=\"h1\">",
"       What is cerebral palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cerebral palsy is a disorder that causes problems with movement and balance. Some babies are born with cerebral palsy, but others get the disorder later on. Babies with cerebral palsy are often slow to roll over, sit, crawl, or walk. The symptoms last for life, but they don&rsquo;t get worse over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22197819\">",
"      <span class=\"h1\">",
"       What are the symptoms of cerebral palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of cerebral palsy can be mild or more serious. Many symptoms are caused by weakness or stiffness of parts of the body. These symptoms change as the baby gets older (",
"      <a class=\"graphic graphic_table graphicRef82772 \" href=\"mobipreview.htm?40/9/41115\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Many children with cerebral palsy also have other problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble drinking or eating &ndash; This can lead to other problems, including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Not gaining enough weight",
"       </li>",
"       <li>",
"        Choking",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lung infections",
"       </li>",
"       <li>",
"        Trouble thinking and learning",
"       </li>",
"       <li>",
"        Problems with hearing and speaking",
"       </li>",
"       <li>",
"        Trouble seeing &ndash; Many children with cerebral palsy have one eye that turns in or out.",
"       </li>",
"       <li>",
"        Seizures - Seizures are waves of abnormal electrical activity in the brain. They can make a child pass out, or move or behave strangely.",
"       </li>",
"       <li>",
"        Short limbs &ndash; A child with symptoms of cerebral palsy on one side of the body might have a shorter leg or arm on the affected side.",
"       </li>",
"       <li>",
"        A curved spine (called &ldquo;scoliosis&rdquo;)",
"       </li>",
"       <li>",
"        Stiff joints",
"       </li>",
"       <li>",
"        Problems with &ldquo;spatial awareness&rdquo; &ndash; This means the child cannot tell the position of his or her arm, leg, or hand.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22197834\">",
"      <span class=\"h1\">",
"       Are there tests for cerebral palsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your child&rsquo;s doctor or nurse might be able to tell if your child has cerebral palsy by doing an exam and learning about your child&rsquo;s symptoms. But doctors can&rsquo;t always tell because children develop at different rates during the first 2 years of life. He or she might refer you to a specialist to help find out if your child has cerebral palsy.",
"     </p>",
"     <p>",
"      Possible tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An MRI &ndash; This is an imaging test that takes pictures of the inside of the brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An EEG - An EEG is a test that measures electrical activity in the brain and records brain wave patterns. A doctor might do this test if your child has seizures.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22197849\">",
"      <span class=\"h1\">",
"       How is cerebral palsy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will refer you to an &ldquo;early intervention&rdquo; program. These programs have different types of experts. They will teach you how to help your child do everyday things he or she might have trouble doing. These include eating, speaking, walking, and learning.",
"     </p>",
"     <p>",
"      Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Your child&rsquo;s doctor might prescribe medicines that help treat symptoms such as stiff muscles, unusual body movements, or seizures.",
"       </li>",
"       <li>",
"        Equipment &ndash; These include devices such as leg braces, walkers, or a wheelchair to help your child get around.",
"       </li>",
"       <li>",
"        Nutrition &ndash; Some children need special diets to help them gain enough weight to be healthy. Some children need to get some or all of their food through a tube that goes directly into the stomach. This is called a &ldquo;gastrostomy tube&rdquo; or &ldquo;g-tube.&rdquo;",
"       </li>",
"       <li>",
"        Surgery &ndash; For children with very severe symptoms, doctors sometimes do surgery to put the child&rsquo;s legs or arms into a correct position.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22197864\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children with mild forms of cerebral palsy often live as long as people who don&rsquo;t have the disorder. Children with more serious forms of the disease might not live as long. Special equipment and teaching can help your child move and learn as much as he or she can.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?29/8/29825?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82901 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29825=[""].join("\n");
var outline_f29_8_29825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22197804\">",
"      What is cerebral palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22197819\">",
"      What are the symptoms of cerebral palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22197834\">",
"      Are there tests for cerebral palsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22197849\">",
"      How is cerebral palsy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22197864\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/9/41115\">",
"      Cerebral palsy symptoms at different ages",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29826="Arteriovenous malformation I";
var content_f29_8_29826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation in the right upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal CT image with lung window settings shows a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29826=[""].join("\n");
var outline_f29_8_29826=null;
var title_f29_8_29827="Clinical testing for pemphigoid";
var content_f29_8_29827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Clinical testing algorithm for bullous pemphigoid and mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 739px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin dashed lines represent negative. Larger dashed lines represent specimen tests. Solid lines represent positive.",
"    <div class=\"footnotes\">",
"     BMZ: basement membrane zone; DIF: direct immunofluorescence; ELISA: enzyme-linked immunosorbent assay; H&amp;E;: hematoxylin and eosin histology stain; IIF: indirect immunofluorescence.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29827=[""].join("\n");
var outline_f29_8_29827=null;
var title_f29_8_29828="Nabilone: Patient drug information";
var content_f29_8_29828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nabilone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"     see \"Nabilone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/35/30260?source=see_link\">",
"     see \"Nabilone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2980459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F554086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;;",
"     </li>",
"     <li>",
"      PMS-Nabilone;",
"     </li>",
"     <li>",
"      RAN&trade;-Nabilone;",
"     </li>",
"     <li>",
"      Teva-Nabilone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nabilone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse drugs, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To stop upset stomach from chemo, take 1 to 3 hours before chemo.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11800 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29828=[""].join("\n");
var outline_f29_8_29828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980459\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554086\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014249\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014248\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014253\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014254\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014256\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014251\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014252\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014257\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014258\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=related_link\">",
"      Nabilone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/35/30260?source=related_link\">",
"      Nabilone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29829="Neonatal acne";
var content_f29_8_29829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonatal acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and pustules on the cheeks of a 3-week-old neonate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George A Datto, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29829=[""].join("\n");
var outline_f29_8_29829=null;
var title_f29_8_29830="Metabolic bone disease in primary biliary cirrhosis";
var content_f29_8_29830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metabolic bone disease in primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Raoul Poupon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29830/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/8/29830/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic osteodystrophy refers to the structural and metabolic bone changes seen in patients with chronic liver disease and includes both osteoporosis and osteomalacia. Osteoporosis is a skeletal condition characterized by low bone mass, whereas osteomalacia is a disorder of decreased mineralization of newly formed osteoid at sites of bone turnover. Both disorders put patients at risk for fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review metabolic bone disease in patients with primary biliary cirrhosis (PBC). The discussion that follows is consistent with the 2003 guidelines issued by The American Gastroenterological Association (AGA) regarding osteoporosis in patients with liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These guidelines, as well as other AGA guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     AGA web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other issues related to metabolic bone disease, including metabolic bone disease following liver transplantation and a detailed discussion of treatment approaches for osteoporosis, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15421748\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of osteoporosis among patients with PBC range from 14 to 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/3\">",
"     3",
"    </a>",
"    ]. One reason that osteoporosis is common in PBC is that many patients with PBC are postmenopausal women, a group already at increased risk for osteoporosis. In addition to age and postmenopausal status, other factors associated with an increased risk for osteoporosis among patients with PBC include lower weight, shorter height, more advanced fibrosis on liver biopsy, hypogonadism, and increasing severity and duration of PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. The prevalence of osteoporosis appears to be decreasing over time, likely related to improved treatment for PBC. In one study, the prevalence of osteoporosis between 1987 and 1995 was 37 percent, whereas between 2002 and 2007 it was 21 percent, though the difference did not reach statistical significance.",
"   </p>",
"   <p>",
"    Osteoporosis has been shown to be a risk factor for vertebral and nonvertebral fractures in women with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/6\">",
"     6",
"    </a>",
"    ], and the prevalence of fractures among patients with PBC is approximately 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/2\">",
"     2",
"    </a>",
"    ]. In a study of 185 women with PBC, fractures were seen in 21 percent. Risk factors for fractures included osteoporosis, menopause, age, and height. When compared with the general population, the absolute increase in fracture risk is moderately increased. In a population-based study, patients with PBC had a twofold increased risk of any fracture compared with the general population, with an absolute excess fracture rate of 12.5 per 1000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike osteoporosis, which is common among patients with PBC, osteomalacia is rarely seen now that there is better medical treatment for many patients with PBC and liver transplantation for those with advanced PBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332402697\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of osteoporosis in patients with PBC has, in most reports, been directly related to the duration and severity of PBC and to the intensity and duration of jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, the mechanisms responsible for the development of osteoporosis in patients with PBC are not well understood. The plasma concentrations of vitamin D metabolites and calcium are usually normal. Biochemical and bone histomorphometric studies suggest that these patients, particularly in the precirrhotic stage, have a \"low-turnover\" osteoporosis, in which bone formation is inhibited and bone resorption is low or normal, although the mechanism(s) causing these changes are not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/9,11-14\">",
"     9,11-14",
"    </a>",
"    ]. One theory suggests that a toxin (or toxins) retained because of cholestasis prevents the osteoblast from functioning normally, resulting in decreased bone formation.",
"   </p>",
"   <p>",
"    It was initially proposed that decreased bile salt flow, leading to malabsorption of vitamin D, was responsible for the development of osteoporosis. However, this hypothesis is most likely incorrect given the observations that the plasma concentration of calcidiol (25-hydroxyvitamin D) and calcitriol (1,25 dihydroxyvitamin D) are normal in PBC patients with osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/2\">",
"     2",
"    </a>",
"    ] and that vitamin D repletion in the minority of cases with low plasma levels does not improve the severity of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/10,14-16\">",
"     10,14-16",
"    </a>",
"    ]. However, these data should be interpreted with caution because vitamin D assays vary and there is not a single agreed upon definition for vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332402879\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with osteoporosis do not have symptoms related to their bone disease. When symptoms do occur, they are related to fractures. The most common fractures are vertebral fractures, two-thirds of which are asymptomatic and are diagnosed as incidental findings on a chest or abdominal x-ray. In some patients, vertebral fractures may result in loss of height, kyphosis, or acute back pain (",
"    <a class=\"graphic graphic_figure graphicRef65879 \" href=\"mobipreview.htm?34/19/35120\">",
"     figure 1",
"    </a>",
"    ). Other fractures seen in patients with osteoporosis include hip fractures and distal radius fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18937?source=see_link&amp;anchor=H4487423#H4487423\">",
"     \"Hip fractures in adults\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332402908\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in patients without PBC, the diagnosis of osteoporosis is made with bone mineral density testing of the lumbar spine and hip. This is typically done using dual-energy x-ray absorptiometry (DXA) (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"mobipreview.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H7#H7\">",
"     \"Screening for osteoporosis\", section on 'Bone density'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone mineral density testing should be performed (",
"    <a class=\"graphic graphic_algorithm graphicRef52724 \" href=\"mobipreview.htm?3/29/3538\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When PBC is diagnosed",
"     </li>",
"     <li>",
"      In patients with a fragility fracture",
"     </li>",
"     <li>",
"      Prior to liver transplantation",
"     </li>",
"     <li>",
"      In patients with cirrhosis",
"     </li>",
"     <li>",
"      In patients receiving glucocorticoids for more than three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osteoporosis in postmenopausal women and in men age 50 years and older is defined by a bone mineral density that is &ge;2.5 standard deviations below the average value of young adults (T-score), whereas osteopenia is defined by a value more than 1 standard deviation but less than 2.5 standard deviations below (",
"    <a class=\"graphic graphic_table graphicRef53999 \" href=\"mobipreview.htm?6/54/7019\">",
"     table 2",
"    </a>",
"    ). In premenopausal women and in men under the age of 50 years, osteoporosis is defined by a bone mineral density that is &ge;2.0 standard deviations below the average value of an age-matched population (Z-score), provided other risk factors for osteoporosis (including PBC and glucocorticoid use) are present.",
"   </p>",
"   <p>",
"    In addition, any patient with a fragility fracture is considered to have osteoporosis. A fragility fracture is any fracture (aside from a fracture of the digits) that occurs from a standing height or less without major trauma such as a motor vehicle accident.",
"   </p>",
"   <p>",
"    In patients without osteoporosis, the AGA guidelines recommend follow-up bone mineral density testing after two to three years, but acknowledge that data are lacking regarding how often testing should be repeated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. A shorter follow-up interval is recommended for patients taking high-dose glucocorticoids or with osteopenia. In addition, while not addressed in the AGA guidelines, we repeat bone mineral density testing yearly in patients with osteopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58558900\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia may have similar radiographic and bone mineral density findings. While only a bone biopsy can truly distinguish osteoporosis from osteomalacia, bone biopsies are usually not required because osteomalacia is rare in PBC and the disorders causing osteomalacia can be diagnosed by biochemical testing.",
"   </p>",
"   <p>",
"    If the diagnosis is not clear, measurement of plasma levels of 25-hydroxyvitamin D (25OHD, calcidiol), calcium, phosphate, and alkaline phosphatase should be obtained. Osteoporosis is characterized by normal serum levels of calcium, phosphate, alkaline phosphatase, and parathyroid hormone. This is in contrast to the frequent findings of one or more of the following in osteomalacia: hypophosphatemia, hypocalcemia, low levels of 25OHD (&lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [25",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    secondary hyperparathyroidism, and increased alkaline phosphatase (",
"    <a class=\"graphic graphic_table graphicRef65400 \" href=\"mobipreview.htm?15/57/16284\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/18\">",
"     18",
"    </a>",
"    ]. Although 25OHD levels may be low in patients with osteoporosis, and a subset of these patients may also have secondary elevations of parathyroid hormone, 25OHD levels rarely are below 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link&amp;anchor=H15280944#H15280944\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the prevention or treatment of osteoporosis depends upon factors such as the patient's bone mineral density, age, and whether the patient has hypogonadism (",
"    <a class=\"graphic graphic_algorithm graphicRef52724 \" href=\"mobipreview.htm?3/29/3538\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/1\">",
"     1",
"    </a>",
"    ]. Calcium and vitamin D are recommended for all patients, along with lifestyle modifications. Pharmacologic therapy, often a bisphosphonate, is recommended for patients with osteoporosis, fragility fractures, or who require prolonged treatment with glucocorticoids. The management of such patients is similar to that for other patients who have osteoporosis or who require prolonged treatment with glucocorticoids. However, we avoid oral bisphosphonates in patients with esophageal varices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with PBC who undergo liver transplantation often have improvement in their osteoporosis. Liver transplantation is associated with increased bone mineral density in patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], though bone loss is accelerated for the first three to six months after transplantation (",
"    <a class=\"graphic graphic_figure graphicRef68819 \" href=\"mobipreview.htm?10/34/10797\">",
"     figure 2",
"    </a>",
"    ). Calcium supplementation is particularly important after liver transplantation because of the high calcium requirements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OSTEOMALACIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia, characterized by decreased bone mineralization, is now rarely seen in PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/9,10,12,15\">",
"     9,10,12,15",
"    </a>",
"    ]. When present, it is typically associated with vitamin D deficiency, with or without concomitant fat malabsorption. Malabsorption of vitamin D may be exacerbated by the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The clinical presentation of osteomalacia (bone pain and fractures) and radiographic findings are similar to those in osteoporosis, although often more severe. Thus, the definitive diagnosis can be established only by bone biopsy. However, this is not usually necessary if the plasma levels of 25-hydroxyvitamin D (25OHD, calcidiol) and parathyroid hormone are normal, since osteomalacia is highly unlikely in this setting. However, there are rare cases of true calcium malabsorption, which can lead to osteomalacia in the setting of normal 25OHD and parathyroid hormone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H58558900\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients found to have a low plasma 25OHD concentration (ie, &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    which typically leads to secondary hyperparathyroidism, are assumed to be at risk for osteomalacia and should be treated with high doses of vitamin D and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29830/abstract/21\">",
"     21",
"    </a>",
"    ]. The goal is to normalize the plasma calcidiol (250HD) concentration and to alleviate the signs and symptoms of osteomalacia. This will often require several thousand units per day, or 50,000 units of vitamin D2 given once or twice weekly. This regimen should be continued indefinitely (unless the PBC is corrected by liver transplantation) since the patient is presumed to be at risk for recurrent vitamin D deficiency. In addition, 25OHD levels should be normalized (&gt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    prior to considering antiresorptive therapy with an intravenous bisphosphonate due to a small but measurable risk of hypocalcemia in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H6#H6\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'IV regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic bone disease seen in patients with primary biliary cirrhosis (PBC) includes osteoporosis and osteomalacia. Osteoporosis is a skeletal condition characterized by low bone mass, whereas osteomalacia is a disorder of decreased mineralization of newly formed osteoid at sites of bone turnover. Both disorders put patients at risk for fractures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of the prevalence of osteoporosis among patients with PBC range from 14 to 52 percent, whereas osteomalacia is rarely seen. (See",
"      <a class=\"local\" href=\"#H15421748\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with osteoporosis are asymptomatic from their bone disease. When symptoms do occur, they are related to fractures. (See",
"      <a class=\"local\" href=\"#H332402879\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of osteoporosis is made with bone mineral density testing of the lumbar spine and hip. This is typically done using dual-energy x-ray absorptiometry. Osteoporosis is defined by a bone mineral density that is more than 2.5 standard deviations below the average value of young adults, whereas osteopenia is defined by a value more than 1 standard deviation but less than 2.5 standard deviations below average (",
"      <a class=\"graphic graphic_table graphicRef53999 \" href=\"mobipreview.htm?6/54/7019\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Bone mineral density testing should be performed (see",
"      <a class=\"local\" href=\"#H332402908\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When PBC is diagnosed",
"     </li>",
"     <li>",
"      In patients with a fragility fracture",
"     </li>",
"     <li>",
"      Prior to liver transplantation",
"     </li>",
"     <li>",
"      In patients with cirrhosis",
"     </li>",
"     <li>",
"      In patients receiving glucocorticoids for more than three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to the prevention or treatment of osteoporosis depends upon factors such as the patient's bone mineral density, age, and whether the patient has hypogonadism (",
"      <a class=\"graphic graphic_algorithm graphicRef52724 \" href=\"mobipreview.htm?3/29/3538\">",
"       algorithm 1",
"      </a>",
"      ). Calcium and vitamin D are recommended for all patients, along with lifestyle modifications. Pharmacologic therapy, typically a bisphosphonate, is recommended for patients with osteoporosis, fragility fractures, or who require prolonged treatment with glucocorticoids. The management of such patients is similar to that for other patients who have osteoporosis or who require prolonged treatment with glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with PBC who undergo liver transplantation often have improvement in their osteoporosis. Liver transplantation is associated with increased bone mineral density in patients with PBC, though bone loss is accelerated for the first three to six months after transplantation (",
"      <a class=\"graphic graphic_figure graphicRef68819 \" href=\"mobipreview.htm?10/34/10797\">",
"       figure 2",
"      </a>",
"      ). Calcium supplementation is particularly important after liver transplantation because of the high calcium requirements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22755185\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/1\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003; 125:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/2\">",
"      Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/3\">",
"      Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2010; 22:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/4\">",
"      Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/5\">",
"      Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/6\">",
"      Gua&ntilde;abens N, Cerd&aacute; D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/7\">",
"      Mounach A, Ouzzif Z, Wariaghli G, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 2008; 26:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/8\">",
"      Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/9\">",
"      Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/10\">",
"      Matloff DS, Kaplan MM, Neer RM, et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/11\">",
"      Gua&ntilde;abens N, Par&eacute;s A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/12\">",
"      Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/13\">",
"      Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/14\">",
"      Fogelman I, Ryan P. Measurement of bone mass. Bone 1992; 13 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/15\">",
"      Camisasca M, Albisetti W, Grandinetti G, et al. Bone disease in primary biliary cirrhosis (PBC): A large scale prevalence study (abstract). Eur J Gastroenterol Hepatol 1991; 3:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/16\">",
"      Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/17\">",
"      Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/18\">",
"      Bingham CT, Fitzpatrick LA. Noninvasive testing in the diagnosis of osteomalacia. Am J Med 1993; 95:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/19\">",
"      Hamburg SM, Piers DA, van den Berg AP, et al. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/20\">",
"      Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29830/abstract/21\">",
"      Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:889.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3606 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29830=[""].join("\n");
var outline_f29_8_29830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15421748\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332402697\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332402879\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332402908\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58558900\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OSTEOMALACIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22755185\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3606|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?3/29/3538\" title=\"algorithm 1\">",
"      Mgmt osteoporosis liver dz AGA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3606|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/19/35120\" title=\"figure 1\">",
"      Spinal curve osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/34/10797\" title=\"figure 2\">",
"      BMD after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/28/11723\" title=\"table 1\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/54/7019\" title=\"table 2\">",
"      Bone mineral density T-score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/57/16284\" title=\"table 3\">",
"      Lab findings in osteomalacia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18937?source=related_link\">",
"      Hip fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29831="Approach to the patient with macular skin lesions";
var content_f29_8_29831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with macular skin lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29831/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/8/29831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macules are nonpalpable lesions that vary in pigmentation from the surrounding skin. Macules are not raised or atrophic; clinicians must consider other salient features to assist in developing a reasonable differential diagnosis. Often clinicians state that a dermatologic lesion is \"macular-papular,\" when in fact the lesion's morphology is papules and plaques, not macules. Definitions of dermatologic lesions can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35541?source=see_link\">",
"     \"Approach to dermatologic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relatively few dermatologic disorders account for the majority of conditions presenting with only macules. Thus, the presence of these lesions can aid in forming an accurate diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61066 \" href=\"mobipreview.htm?36/18/37164\">",
"     table 1",
"    </a>",
"    ). One to two isolated macules in young children are often not pathological; in adults such lesions may occur frequently as a result of sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of macules should raise the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the distribution of the lesion?",
"     </li>",
"     <li>",
"      Is there erythema, hypo- or hyperpigmentation?",
"     </li>",
"     <li>",
"      Are there secondary characteristics such as scale or erythema?",
"     </li>",
"     <li>",
"      Is pruritus present?",
"     </li>",
"     <li>",
"      Is the patient taking any medications, such as prescription, over-the-counter, or herbal?",
"     </li>",
"     <li>",
"      Is there a photodistribution to the eruption?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ERYTHEMATOUS MACULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythematous macules are frequently caused by either viral exanthems or drug eruptions (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    ). Viral exanthems and drug eruptions tend to be diffuse with the majority of the eruption presenting as isolated, blanching erythematous macules on the trunk and proximal extremities. Specific features may characterize certain exanthems, such as the reticulated erythematous eruption associated with erythema infectiosum (",
"    <a class=\"graphic graphic_picture graphicRef75125 \" href=\"mobipreview.htm?11/27/11696\">",
"     picture 1",
"    </a>",
"    ) or the diffuse erythema and perineal accentuation seen in Kawasaki's disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHOTODISTRIBUTED MACULAR ERUPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodistributed macular eruptions may occur in a variety of skin conditions, including dermatomyositis, systemic lupus erythematosus, porphyria cutanea tarda, drug reactions, and polymorphous light eruptions. Photodistributed lesions often have accentuation on the face, the V of the neck, or the dorsa of the hands and forearms, sparing the infranasal and submental areas. Patients may present with lesions involving one or more sun-exposed areas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27142?source=see_link\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dermatomyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In dermatomyositis, the upper eyelids tend to develop a macular purplish hue and edema (",
"    <a class=\"graphic graphic_picture graphicRef73090 \" href=\"mobipreview.htm?0/26/418\">",
"     picture 2",
"    </a>",
"    ). Confluent violaceous erythema may also be present on the arms, shoulders, upper back, or \"v\" area of the neck and upper chest, and is often pruritic (",
"    <a class=\"graphic graphic_picture graphicRef51164 \" href=\"mobipreview.htm?8/9/8351\">",
"     picture 3",
"    </a>",
"    ). Areas of previous diffuse erythema may resolve with persistent poikiloderma (characterized by telangiectasia, mottled pigmentation, and some atrophy).",
"   </p>",
"   <p>",
"    Mottled erythema and dilated superficial blood vessels, telangiectasia, are seen on the hands, particularly at the proximal nail fold (",
"    <a class=\"graphic graphic_picture graphicRef59545 \" href=\"mobipreview.htm?23/61/24532\">",
"     picture 4",
"    </a>",
"    ). Erythematous papules (Gottron's sign) may occur over the knuckles, knees, and elbows (",
"    <a class=\"graphic graphic_picture graphicRef70904 graphicRef50909 \" href=\"mobipreview.htm?5/47/5879\">",
"     picture 5A-B",
"    </a>",
"    ). Patients may exhibit systemic symptoms such as fatigue, arthralgias, or other cutaneous findings. Skin findings can precede the onset of systemic disease or the disease may limit itself to the skin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus tends to present with erythema in a malar distribution, the classic \"butterfly rash\" of the central face (",
"    <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"mobipreview.htm?36/46/37608\">",
"     picture 6A-B",
"    </a>",
"    ), in addition to diffuse erythema in other sun-exposed locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/3\">",
"     3",
"    </a>",
"    ]. The additional presence of oral ulcerations may assist in making the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Photodrug reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of taking a photosensitizing drug suggests the possibility of a photodrug eruption.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phototoxic eruptions are the most common drug-induced photoeruption. The eruption is typically an exaggerated sunburn, often with blisters (",
"      <a class=\"graphic graphic_picture graphicRef86479 \" href=\"mobipreview.htm?35/46/36582\">",
"       picture 7",
"      </a>",
"      ). Nonsteroidal antiinflammatory drugs (NSAIDs), quinolones, tetracyclines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and the phenothiazines are the most frequent causes of phototoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/4\">",
"       4",
"      </a>",
"      ]. The eruption typically occurs with a higher cumulative dose of medication, in contrast to photoallergic drug eruptions, which can occur at any dose. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link&amp;anchor=H22#H22\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Phototoxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Photoallergy is a lymphocyte-mediated reaction caused by exposure to ultraviolet A. The eruption is characterized by widespread eczema in the photodistribution: face; upper chest; and back of hands (",
"      <a class=\"graphic graphic_picture graphicRef63557 \" href=\"mobipreview.htm?7/46/7907\">",
"       picture 8",
"      </a>",
"      ). Most photoallergic reactions are caused by topical agents including biocides added to soaps (halogenated phenolic compounds) and fragrances such as musk ambrette and 6-methyl coumarin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/5\">",
"       5",
"      </a>",
"      ]. Systemic photoallergens such as the phenothiazines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      , sulfa products, and NSAIDs can produce photoallergic reactions, although most of their photosensitive reactions are phototoxic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link&amp;anchor=H25#H25\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Photoallergy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Porphyria cutanea tarda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda may present as diffuse erythema in a photodistributed pattern. Typically there are also vesicles or bullae, scarring, and hypertrichosis (",
"    <a class=\"graphic graphic_picture graphicRef74528 graphicRef78547 \" href=\"mobipreview.htm?25/16/25863\">",
"     picture 9A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link&amp;anchor=H4530124#H4530124\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Skin findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polymorphous light eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphous light eruption is a diagnosis of exclusion. Once all of the above conditions have been considered, a light-induced, pruritic eruption, particularly occurring with the first intense sun exposure of the year, may be consistent with this diagnosis. Polymorphous light eruption can present simply as diffuse erythema. Look for accentuation of the eruption on the arms and thighs; the face may be spared entirely or only slightly involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20455?source=see_link\">",
"     \"Polymorphous light eruption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPOPIGMENTED MACULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopigmented macules are distinguished from depigmented macules by retention of some pigment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vitiligo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitiligo presents primarily as an acquired, isolated or diffuse depigmentation (",
"    <a class=\"graphic graphic_picture graphicRef72369 \" href=\"mobipreview.htm?35/34/36385\">",
"     picture 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/6\">",
"     6",
"    </a>",
"    ]. Hypopigmented areas may also occur during the process of developing or resolving vitiligo. Vitiligo is an autoimmune process against melanocytes; the etiology is unknown. Depigmented areas at birth can also represent ash leaf spots seen in tuberous sclerosis, nevus depigmentosus, nevus anemicus, and poikilosis, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=see_link\">",
"     \"Vitiligo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tinea versicolor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopigmentation, particularly on the trunk and proximal extremities, in a mottled distribution, is suggestive of tinea versicolor. Lesions may also be light brown or salmon colored (",
"    <a class=\"graphic graphic_picture graphicRef59533 graphicRef78860 \" href=\"mobipreview.htm?22/17/22807\">",
"     picture 11A-B",
"    </a>",
"    ). Tinea versicolor may seem to be photoaccentuated as the areas involved fail to tan and become more prominent with sun exposure. This disorder is seen in young adults and those living in humid climates. The diagnosis is confirmed with a positive KOH prep for yeast and hyphae. Erythrasma, a bacterial infection, is a similar appearing eruption that is",
"    <span class=\"nowrap\">",
"     pink/brown,",
"    </span>",
"    slightly scaly, and occurs in the inguinal region (",
"    <a class=\"graphic graphic_picture graphicRef51713 \" href=\"mobipreview.htm?42/36/43587\">",
"     picture 12",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3320?source=see_link\">",
"     \"Tinea versicolor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11959?source=see_link\">",
"     \"Erythrasma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Halo nevus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A halo nevus is a depigmented macule that presents in conjunction with a preexisting pigmented lesion. A halo nevus is caused by a T-cell mediated immune reaction with melanocytic nevus cells, ultimately causing the loss of all pigmentation of and around a nevus (",
"    <a class=\"graphic graphic_picture graphicRef57744 \" href=\"mobipreview.htm?33/28/34240\">",
"     picture 13",
"    </a>",
"    ). Halo nevi are typically a benign process, but occasionally may be associated with the presence of an atypical melanocytic lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=see_link&amp;anchor=H18#H18\">",
"     \"Acquired melanocytic nevi (moles)\", section on 'Halo nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pityriasis alba",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pityriasis alba occurs predominantly in children aged 3 to 16 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/9\">",
"     9",
"    </a>",
"    ]. It is characterized by patches of hypopigmentation, usually distributed on the face, neck, upper trunk, and proximal extremities (",
"    <a class=\"graphic graphic_picture graphicRef60866 graphicRef73576 \" href=\"mobipreview.htm?14/55/15219\">",
"     picture 14A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The lesions range from 0.5 to 5 cm in diameter, with well defined but somewhat irregular borders, and fine scale. They usually are asymptomatic, but may be pruritic. Patients often present after sun exposure when the contrast between affected and nonaffected areas is accentuated by tanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pityriasis alba is thought to represent a nonspecific dermatitis with residual postinflammatory hypopigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. It is associated with atopy, sun exposure, and frequency of bathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The affected sites and surrounding areas should be protected from sun exposure. Mild topical glucocorticoids or calcineurin inhibitors and emollients decrease dryness and scale and may accelerate repigmentation, which typically takes months to years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/10,11,14\">",
"     10,11,14",
"    </a>",
"    ]. Moisturization during the winter months may prevent recurrence in subsequent summers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some systemic conditions, such as cutaneous T cell lymphoma and leprosy can present with hypopigmented lesions on the trunk and extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Sarcoidosis can also present as areas of splotchy hypopigmentation, typically on the anterior lower extremities. Typical systemic and pulmonary findings of sarcoidosis may appear simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HYPERPIGMENTED MACULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpigmented macules may signify several different disease processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Postinflammatory hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse hyperpigmentation often accompanies postinflammatory hyperpigmentation, which can occur anywhere after an inciting eruption has resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/17\">",
"     17",
"    </a>",
"    ]. Postinflammatory hyperpigmentation is particularly common in darker skin types when inflammatory conditions such as acne, psoriasis, or eczema are resolving (",
"    <a class=\"graphic graphic_picture graphicRef78119 \" href=\"mobipreview.htm?20/25/20885\">",
"     picture 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Melasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melasma occurs as splotchy hyperpigmented macules, typically in a photodistributed pattern, often with accentuation on the upper lip (",
"    <a class=\"graphic graphic_picture graphicRef64109 graphicRef52220 \" href=\"mobipreview.htm?5/19/5432\">",
"     picture 16A-B",
"    </a>",
"    ). Melasma tends to occur most commonly in pregnancy and in conjunction with exogenous hormones, but may also occur in males. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33092?source=see_link\">",
"     \"Melasma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Solar purpura (senile purpura)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solar purpura (also called actinic purpura, or Bateman purpura) is a common form of non-inflammatory purpura. It presents as ecchymotic lesions predominantly on the sun-damaged skin of the forearms and dorsa of the hands of elderly individuals (",
"    <a class=\"graphic graphic_picture graphicRef54977 \" href=\"mobipreview.htm?39/62/40943\">",
"     picture 17",
"    </a>",
"    ). These lesions result from rupture of superficial blood vessels with subsequent extravasation of blood in the dermis following a minor trauma. The incidence and severity of solar purpura are increased in individuals taking anticoagulants or corticosteroids. The ecchymoses may persist for several weeks and resolve spontaneously without undergoing the usual sequential color changes of a normal bruise. Residual hyperpigmentation can be observed.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1614701\">",
"    <span class=\"h2\">",
"     Erythema ab igne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema ab igne is a reticular erythematous pigmented dermatosis resulting from repeated exposures to moderate heat or infrared radiation. Once common among people who sat near open fires or stoves, it is infrequently seen after the introduction of central heating. However, it is still seen in relation to occupational exposure to heat sources (foundry workers, bakers), use of hot water bottles, heating pads or blankets(",
"    <a class=\"graphic graphic_picture graphicRef72011 \" href=\"mobipreview.htm?33/30/34287\">",
"     picture 18",
"    </a>",
"    ), heated car seats, and among laptop users who hold the computer on their thighs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. It can occur at any site, more often in an asymmetrical distribution, and is usually asymptomatic. The early skin changes of erythema ab igne usually clear spontaneously in several weeks to months, after the removal of the heat source from the skin. However, longstanding lesions may be associated with permanent hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef52027 \" href=\"mobipreview.htm?9/51/10033\">",
"     picture 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Solar lentigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solar lentigo, most commonly known as liver spots or \"old age'' spots, is a proliferation of normal melanocytes secondary to chronic solar damage. These lesions occur most commonly in whites with fair complexion who have a history of chronic sun exposure. Hyperpigmentation may vary from light to dark brown, but is uniform within an individual lesion. The diagnosis is based upon the clinical appearance of flat, oval, evenly pigmented macules in (",
"    <a class=\"graphic graphic_picture graphicRef86484 graphicRef61452 \" href=\"mobipreview.htm?24/49/25368\">",
"     picture 20A-B",
"    </a>",
"    ) areas of chronic sun exposure, particularly the face, dorsa of the hands, shoulders, and back. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link\">",
"     \"Overview of benign lesions of the skin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Schamberg's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schamberg's disease, also called Schamberg's purpura is a type of pigmented purpuric dermatosis characterized by brownish discoloration of the skin, particularly of the lower extremities and ankle area (",
"    <a class=\"graphic graphic_picture graphicRef67127 \" href=\"mobipreview.htm?25/34/26159\">",
"     picture 21",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/21\">",
"     21",
"    </a>",
"    ]. It is caused by capillary leakage of blood and subsequent breakdown, resulting in hemosiderin staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ochronosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ochronosis is a term used to describe pigment deposition that occurs in the connective tissues of patients with alkaptonuria, an autosomal recessive disorder that results from a deficiency of homogentisic acid oxidase (",
"    <a class=\"graphic graphic_picture graphicRef60616 \" href=\"mobipreview.htm?30/16/30981\">",
"     picture 22",
"    </a>",
"    ). Brown or blue-gray discoloration of the skin may be seen on the axillary and inguinal areas, face, palms, or soles. In addition, blue-black discoloration can be apparent on skin overlying cartilage in which the pigment is deposited, such as the ears. The sclerae are also typically involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23624?source=see_link&amp;anchor=H19#H19\">",
"     \"Disorders of tyrosine metabolism\", section on 'Alkaptonuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"exogenous ochronosis\" is used to refer to the occurrence of localized blue-gray discoloration of the skin associated with the use of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fixed drug eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fixed drug eruption is characterized acutely by erythematous and edematous plaques with a grayish center or frank bullae, and chronically by a dark postinflammatory pigmentation (",
"    <a class=\"graphic graphic_picture graphicRef73678 \" href=\"mobipreview.htm?19/54/20321\">",
"     picture 23",
"    </a>",
"    ). Favored sites include the mouth (lips and tongue), genitalia, face, and acral areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/4\">",
"     4",
"    </a>",
"    ]. The defining features of this eruption include the postinflammatory hyperpigmentation and the recurrence of lesions at exactly the same site with drug reexposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/4\">",
"     4",
"    </a>",
"    ]. The drugs commonly involved include phenolphthalein (laxatives), tetracyclines, barbiturates, sulfonamides, NSAIDs, and salicylates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A changing, pigmented macule should raise suspicion for melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/22\">",
"     22",
"    </a>",
"    ]. Changes suggestive of a melanoma include asymmetry, change in size (particularly, but not necessarily, larger than 6 mm), irregular or notched borders, change in color, or change in sensation (",
"    <a class=\"graphic graphic_picture graphicRef78826 \" href=\"mobipreview.htm?0/3/54\">",
"     picture 24",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of isolated, stable hyperpigmented macules also includes sun-induced lentigenes, ephelides (freckles), cafe au lait spots, bluish-black lesions (Mongolian spots), or nevi.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    induced hyperpigmentation tends to be isolated, hyperpigmented blue-black macules predominantly located in scars. Isolated or diffuse pinkish brown lesions that urticate upon pressure, rubbing, or heat are suggestive of mastocytomas or",
"    <span class=\"nowrap\">",
"     mastocytosis/urticaria",
"    </span>",
"    pigmentosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29831/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/41/37521?source=see_link\">",
"       \"Patient information: Melasma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macules are flat skin lesions that may occur in a variety of skin disorders. Characteristics such as lesion distribution, color, and associated signs or symptoms are useful for identifying the correct diagnosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photosensitive disorders may present with macular lesions in areas exposed to sunlight. Examples of autoimmune disorders that can exhibit these findings include dermatomyositis and systemic lupus erythematosus. Medications can also induce photodistributed macular skin reactions. Phototoxic drug eruptions resemble an exaggerated sunburn, and may be accompanied by blisters. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Photodistributed macular eruptions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pigmentation is a feature that can assist in the diagnosis of macular skin disorders. Hypopigmented macules may range from lesions that are slightly lighter in color than unaffected skin to completely depigmented areas of skin, as are seen in vitiligo or halo nevi. Hyperpigmented macules may occur as a feature of a primary skin disorder or as a consequence of a preceding inflammatory process (postinflammatory hyperpigmentation). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypopigmented macules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Hyperpigmented macules'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/1\">",
"      Vanderhooft SL, Francis JS, Pagon RA, et al. Prevalence of hypopigmented macules in a healthy population. J Pediatr 1996; 129:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/2\">",
"      Pagnoni A, Kligman AM, Sadiq I, Stoudemayer T. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol 1999; 79:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/3\">",
"      Drenkard C, Villa AR, Reyes E, et al. Vasculitis in systemic lupus erythematosus. Lupus 1997; 6:235.",
"     </a>",
"    </li>",
"    <li>",
"     Stern RS, Shear NH. Cutaneous reactions to drugs and biological modifiers. In: Cutaneous Medicine and Surgery, Arndt KA, LeBoit PE, Robinson JK, Wintroub BU (Eds), W.B. Saunders, Philadelphia 1996. Vol 1, p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/5\">",
"      Gonz&aacute;lez E, Gonz&aacute;lez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/6\">",
"      Jimbow K. Vitiligo. Therapeutic advances. Dermatol Clin 1998; 16:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/7\">",
"      J&oacute;wiak S, Schwartz RA, Janniger CK, et al. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998; 37:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/8\">",
"      Miura Y, Tajima S, Ishibashi A, Hata Y. Multiple anemic macules on the arms: a variant form of nevus anemicus? Dermatology 2000; 201:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/9\">",
"      Leung AK, Feingold M. Pityriasis alba. Am J Dis Child 1986; 140:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/10\">",
"      Galan EB, Janniger CK. Pityriasis alba. Cutis 1998; 61:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/11\">",
"      Lin RL, Janniger CK. Pityriasis alba. Cutis 2005; 76:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/12\">",
"      Blessmann Weber M, Sponchiado de Avila LG, Albaneze R, et al. Pityriasis alba: a study of pathogenic factors. J Eur Acad Dermatol Venereol 2002; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/13\">",
"      Urano-Suehisa S, Tagami H. Functional and morphological analysis of the horny layer of pityriasis alba. Acta Derm Venereol 1985; 65:164.",
"     </a>",
"    </li>",
"    <li>",
"     Eczematous eruptions in childhood. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), WB Saunders, Philadelphia 2006. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/15\">",
"      Choe YB, Park KC, Cho KH. A case of hypopigmented mycosis fungoides. J Dermatol 2000; 27:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/16\">",
"      Sarkar R, Kaur I, Das A, Sharma VK. Macular lesions in leprosy: a clinical, bacteriological and histopathological study. J Dermatol 1999; 26:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/17\">",
"      Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin 2000; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/18\">",
"      Beleznay K, Humphrey S, Au S. Erythema ab igne. CMAJ 2010; 182:E228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/19\">",
"      Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics 2010; 126:e1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/20\">",
"      Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol 2012; 148:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/21\">",
"      Ratnam KV, Su WP, Peters MS. Purpura simplex (inflammatory purpura without vasculitis): a clinicopathologic study of 174 cases. J Am Acad Dermatol 1991; 25:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/22\">",
"      Rocamora V, Puig L, Roman&iacute; J, de Moragas JM. Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Cutis 1999; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/23\">",
"      Alto WA, Clarcq L. Cutaneous and systemic manifestations of mastocytosis. Am Fam Physician 1999; 59:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29831/abstract/24\">",
"      Pollack CV Jr, Pender ES. Recognizing an index case of type 1 neurofibromatosis. Am Fam Physician 1992; 45:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1732 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29831=[""].join("\n");
var outline_f29_8_29831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ERYTHEMATOUS MACULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHOTODISTRIBUTED MACULAR ERUPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Photodrug reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPOPIGMENTED MACULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vitiligo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Halo nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pityriasis alba",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HYPERPIGMENTED MACULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Postinflammatory hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Melasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Solar purpura (senile purpura)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1614701\">",
"      Erythema ab igne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Solar lentigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Schamberg's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ochronosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1732|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/27/11696\" title=\"picture 1\">",
"      Rash in erythema infectiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/26/418\" title=\"picture 2\">",
"      Heliotrope eruption in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/9/8351\" title=\"picture 3\">",
"      shawl sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/61/24532\" title=\"picture 4\">",
"      Dermatomyositis dilated capillary loops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/36/30273\" title=\"picture 5A\">",
"      Gottrons sign in DM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/13/40145\" title=\"picture 5B\">",
"      Gottrons sign in DM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/39/32371\" title=\"picture 6A\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/47/3828\" title=\"picture 6B\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/46/36582\" title=\"picture 7\">",
"      Phototoxic eruption new",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/46/7907\" title=\"picture 8\">",
"      Photoallergic eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/30/13794\" title=\"picture 9A\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14066\" title=\"picture 9B\">",
"      Porphyria cutanea tarda 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/34/36385\" title=\"picture 10\">",
"      Vitiligo segmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/16/10496\" title=\"picture 11A\">",
"      Tinea versicolor arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/17/13588\" title=\"picture 11B\">",
"      Tinea versicolor chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/36/43587\" title=\"picture 12\">",
"      Intertriginous erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/28/34240\" title=\"picture 13\">",
"      Halo nevus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/30/33262\" title=\"picture 14A\">",
"      Pityriasis alba 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/29/22992\" title=\"picture 14B\">",
"      Pityriasis alba 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/25/20885\" title=\"picture 15\">",
"      Acne hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/53/35666\" title=\"picture 16A\">",
"      Melasma cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/24/8579\" title=\"picture 16B\">",
"      Melasma lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/62/40943\" title=\"picture 17\">",
"      Actinic purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/30/34287\" title=\"picture 18\">",
"      Erythema ab igne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/51/10033\" title=\"picture 19\">",
"      Erythema ab igne hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/62/36836\" title=\"picture 20A\">",
"      Solar lentigo back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/10/6306\" title=\"picture 20B\">",
"      Solar lentigo hand 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/34/26159\" title=\"picture 21\">",
"      Schambergs disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/16/30981\" title=\"picture 22\">",
"      Ochronotic pigmentation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/54/20321\" title=\"picture 23\">",
"      Fixed drug hyperpigment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/3/54\" title=\"picture 24\">",
"      Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/18/37164\" title=\"table 1\">",
"      Macules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35541?source=related_link\">",
"      Approach to dermatologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/43/11959?source=related_link\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33092?source=related_link\">",
"      Melasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/41/37521?source=related_link\">",
"      Patient information: Melasma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20455?source=related_link\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3320?source=related_link\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29832="Huntington disease: Clinical features and diagnosis";
var content_f29_8_29832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Huntington disease: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     Oksana Suchowersky, MD, FRCPC, FCCMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29832/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/8/29832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease (HD) is an inherited progressive neurodegenerative disorder characterized by choreiform movements, psychiatric problems, and dementia. It is caused by a trinucleotide (CAG) repeat expansion in the huntingtin gene on chromosome 4p and inherited in an autosomal-dominant pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathophysiology of HD is not fully understood, although it is thought to be related to toxicity of the mutant huntingtin protein.",
"   </p>",
"   <p>",
"    As there is no known cure, treatment is symptomatic and remains supportive. Genetic mouse models are expanding our understanding of the disease and may lead to disease modifying therapy in the future.",
"   </p>",
"   <p>",
"    This topic will review the clinical features and diagnosis of HD. Other aspects of HD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=see_link\">",
"     \"Huntington disease: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY/GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics and pathogenesis of HD are reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Huntington disease is caused by a trinucleotide (CAG) expansion in the huntingtin (HTT) gene (also known as the HD gene) that encodes the protein huntingtin, resulting in an expanded polyglutamine tract. Huntingtin is present in a large number of tissues throughout the body. However, pathology appears to be limited to the central nervous system, with atrophy of the caudate and putamen (the neostriatum) being most prominent. At the cellular level, protein aggregates are seen both in the cytoplasm and nucleus.",
"   </p>",
"   <p>",
"    The pathophysiology of neuron loss is incompletely understood. The huntingtin protein is thought to become toxic with the CAG expansion (\"gain of function\") but continues to serve a function that is critical to survival in early development.",
"   </p>",
"   <p>",
"    HD is an autosomal dominant disorder with full penetrance at repeat sizes greater than 38. Repeat numbers of the CAG expansion &gt;38 in the HTT gene are diagnostic for HD (with the normal range being 15 to 32); repeats in the 33 to 38 size may or may not be penetrant. The main determinate of age of onset is the number of CAG repeats in the HTT gene; repeat size has been estimated to account for approximately 50 percent of the predictors for age of onset. Those individuals with the earliest onset tend to have the largest repeats, while those developing HD late in life correlate with a low repeat number. Rate of disease progression is also inversely related to repeat size. Additional factors predicting age of onset are thought to be environmental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other genetic determinants.",
"   </p>",
"   <p>",
"    As with all trinucleotide disorders, there is genetic instability, although the mechanism remains poorly understood. Expansion of the repeat number between successive generations, which causes an earlier and more severe phenotype, is termed anticipation. Paternal inheritance produces the largest increase, with an average of nine repeats with each generation. Decreases in the number of CAG repeats rarely occur during maternal transmission. Because of these differences in repeat expansion, 70 to 88 percent of juvenile onset patients with large repeat sizes have inherited the gene from their father. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=see_link&amp;anchor=H3#H3\">",
"     \"Huntington disease: Genetics and pathogenesis\", section on 'Anticipation and transmitting parent effect'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 meta-analysis that evaluated HD epidemiology studies published since 1985 made the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The worldwide",
"      <strong>",
"       prevalence",
"      </strong>",
"      of HD was 2.7 per 100,000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In studies from Europe, North America and Australia, the prevalence of HD was 5.7 per 100,000",
"     </li>",
"     <li>",
"      In studies from Asia, the prevalence of HD was 0.4 per 100,000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The worldwide",
"      <strong>",
"       incidence",
"      </strong>",
"      of HD was 0.38 per 100,000 per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences in prevalence among ethnic populations may reflect early founders with the mutation or ascertainment differences among studies.",
"   </p>",
"   <p>",
"    Age of onset ranges from childhood to the eighth decade, but is most common in mid-life. Diagnosis before 20 years of age is considered juvenile HD, or Westphal variant of HD, and comprises less than 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, HD is characterized by chorea, psychiatric illness, and dementia (",
"    <a class=\"graphic graphic_table graphicRef57709 \" href=\"mobipreview.htm?7/42/7852\">",
"     table 1",
"    </a>",
"    ). Symptoms begin insidiously with movement abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with psychiatric and cognitive features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Motor symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key feature of HD, and the defining symptom at the time of diagnosis, is chorea. Chorea is a rapid, involuntary, nonrepetitive or arrhythmic movement involving the face, trunk, and limbs. Initially, the movements are mild and may be misinterpreted as restlessness. Patients may be unaware of the movements and incorporate the chorea into purposeful actions, a phenomenon termed parakinesia. Gradually, the chorea becomes more florid and widespread, interfering with movement. In later stages, chorea also affects the diaphragm, pharynx, and larynx, producing dysarthria, dysphagia, and involuntary vocalizations.",
"   </p>",
"   <p>",
"    Motor impersistence (the inability to sustain certain simple voluntary acts) is another common manifestation of HD. As an example, patients may have difficulty with sustained tongue protrusion.",
"   </p>",
"   <p>",
"    Hypotonia with hyperreflexia is a feature of early disease. Dystonia (prolonged, sustained, abnormal postures) may be seen in the hands with such activities as walking. Mild bradykinesia is also observed.",
"   </p>",
"   <p>",
"    With disease progression, motor function slowly deteriorates, and chorea may eventually be replaced by a parkinsonian akinetic-rigid state in the advanced stages. Walking becomes unsafe when chorea and parkinsonism prevent adequate compensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Eye movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal eye movements can be a prominent finding in HD, particularly in younger adult patients. In patients with early HD, there is delay in the initiation of volitional saccades, and saccade velocity is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. This is characterized by the absence of saccadic movement with preservation of smooth pursuit. Optokinetic nystagmus is abnormal in very early stages. In more advanced stages of HD, smooth pursuit, voluntary saccades, and refixation are all impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present with irritability, depression,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disrupted social relationships up to several years prior to onset of chorea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Over one-half of all patients have symptoms of dysphoria, agitation, irritability, apathy, or anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/14\">",
"     14",
"    </a>",
"    ]. Depression, paranoia, delusions, and hallucinations can develop at any point in the illness, and approximately one-half of patients will meet diagnostic criteria for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/15\">",
"     15",
"    </a>",
"    ]. Psychiatric symptoms do not correlate with duration of disease, repeat length, or presence of dementia or motor symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HD is associated with an increased risk of suicide for diagnosed patients, at-risk family members, and even those shown to be negative for the mutation. The suicide rate of affected individuals is 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/18\">",
"     18",
"    </a>",
"    ]. The significant stress placed on the family unit in relationship to HD is expressed in the high prevalence of psychiatric illness in family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive decline is inevitable in HD. Rarely, patients with onset of HD late in life may have motor symptoms only, presumably because the remaining life span is too short for cognitive symptoms to become obvious.",
"   </p>",
"   <p>",
"    The dominant cognitive feature of HD is executive dysfunction with diminished ability to make decisions, multi-task, and switch from one set of cognitive goals to another. Patients typically lack insight into their cognitive deficits. The dementia of HD, like other non-Alzheimer dementias, has been described in the older literature as \"subcortical\", referring to clinical models of cognition that highlight frontostriatal pathways as facilitators of speed and efficiency of thought.",
"   </p>",
"   <p>",
"    On formal testing, patients with HD find time-based tasks particularly difficult; examples include word fluency, picture sequencing, and the Wisconsin card sorting test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/20\">",
"     20",
"    </a>",
"    ]. When compared with patients who have Alzheimer disease, a type of \"cortical\" dementia, patients with HD display greater improvement with cuing during recall tasks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/21\">",
"     21",
"    </a>",
"    ]. This implies that the difficulty in HD is due to an inefficient search of memory. Despite evidence of cognitive abnormalities early in HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/22\">",
"     22",
"    </a>",
"    ], memory loss is usually a late finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/13\">",
"     13",
"    </a>",
"    ]. Difficulties with other typically cortical functions, such as aphasia and apraxia, are uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Weight loss and cachexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss and cachexia are common features of HD, despite efforts to maintain appropriate caloric intake.",
"   </p>",
"   <p>",
"    The pathophysiology of weight loss is not well-understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/23\">",
"     23",
"    </a>",
"    ]. Some evidence suggests that weight loss correlates with a higher CAG repeat number in mutant huntingtin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/24\">",
"     24",
"    </a>",
"    ]. Possible contributors include energy expenditure due to hyperkinetic movements and altered cellular metabolism in muscle or adipose tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atypical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, adult-onset cases present with either cerebellar-type limb and gait ataxia, myoclonus, seizures, or generalized dystonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. These presentations tend to occur in patients with a younger age of onset (ie, late adolescence or early adulthood). Elderly patients can sometimes present with signs of parkinsonism without tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Juvenile Huntington disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When HD presents before age 20, clinical features include myoclonus, seizures, behavioral problems, and parkinsonism. Chorea is notably absent (",
"    <a class=\"graphic graphic_table graphicRef61297 \" href=\"mobipreview.htm?1/19/1339\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=see_link&amp;anchor=H5#H5\">",
"     \"Bradykinetic movement disorders in children\", section on 'Huntington disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advanced stages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of age of onset, HD is a chronic progressive disease. The slow but relentless deterioration in cognitive and motor function causes significant morbidity and early mortality. Dysphagia may require placement of a feeding tube to maintain adequate nutrition. Complications of immobility, such as aspiration pneumonia and other infections, result in death 10 to 30 years after disease onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prediagnosis manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defining the first symptoms or signs of HD has been the focus of a number of studies of at-risk and asymptomatic patients with HD. Understanding this stage of the illness may allow future therapeutic trials of neuroprotection to focus on delaying clinical onset in those shown to have the huntingtin mutation. The following observations suggest that mutant HTT causes subtle manifestations long before the overt symptoms of HD are recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using quantitative neuropsychologic tests, neurologic examination, and brain imaging, small but statistically significant differences have been reported between asymptomatic HD cases and controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/30-39\">",
"       30-39",
"      </a>",
"      ]. Abnormalities have been found in psychomotor speed, negative emotion recognition, irritability, optokinetic nystagmus, motor performance (eg, rapid alternating hand movements, timing of finger taps), and whole brain volume.",
"     </li>",
"     <li>",
"      Data from studies employing MRI and positron-emission tomography (PET) have shown striatal atrophy and hypometabolism predating any clinical features by up to 20 years in asymptomatic patients with HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. These structural and metabolic changes may explain the early symptoms of HD, and could serve as a biomarker to identify presymptomatic patients who may benefit from therapeutic intervention.",
"     </li>",
"     <li>",
"      A case-control study found that asymptomatic children who were at-risk for HD due to CAG repeat expansion length &ge;39 in the HTT gene had small but statistically significant reductions in mean head circumference, body mass index, weight and height compared with healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these findings, surveys based on analysis of friends and families of patients with HD indicate that the motor disorder is their first indication of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial MRI images through the lateral ventricles demonstrate caudate atrophy, defined by the loss of the normal protrusion of the caudate head into the lateral ventricle in late-stage HD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66811 \" href=\"mobipreview.htm?18/1/18453\">",
"     image 1",
"    </a>",
"    ). Caudate atrophy, quantified by simple analysis of linear caudate measurements, correlates with change in cognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional imaging using positron-emission tomography (PET) and MRI also show abnormal metabolic changes in the caudate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using computational MRI methods, progressive regional thinning of the cerebral cortex has been reported in patients with both preclinical and symptomatic HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. These cortical changes may underlie some of the clinical heterogeneity of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HD is based upon presence of the typical clinical features and a family history of the disease. With the availability of genetic molecular testing, all suspected HD cases can be easily confirmed. Molecular testing can also help avoid unnecessary investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, a family history of genetically proven HD is a key factor in the diagnosis. Siblings or children of an index case who present with symptoms typical of HD can be confidently diagnosed based on a detailed history and physical exam. A careful review of the family history may reveal misdiagnosed parents or grandparents with psychiatric illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suicide.",
"   </p>",
"   <p>",
"    There is no apparent family history in up to 8 percent of patients with genetically proven HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This finding may be due to misdiagnosis in a family member, or death of the affected parent prior to onset or recognition of symptoms. Occasionally, there is no family history of HD because the disease is caused by a new HTT gene mutation in the affected individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is sensitive (98.8 percent) and specific (100 percent) for HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/51\">",
"     51",
"    </a>",
"    ]. It allows for easy confirmation of clinical diagnosis, diagnosis of atypical patients, and presymptomatic testing in at-risk individuals. Each scenario has implications regarding the test results. For those without a family history, genetic confirmation of HD has significant implications for other at-risk family members. Decisions of family planning or implications to children of the index case also need special management.",
"   </p>",
"   <p>",
"    In patients with a typical HD phenotype, genetic testing is negative in approximately one percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In such cases, several genetically heterogeneous disorders that are phenotypically similar to HD should be considered, such as dentatorubral pallidoluysian atrophy (DRPLA), Huntington disease-like syndrome 2 (HDL2), spinocerebellar ataxia type 17, familial prion disease, and Friedreich's ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/53\">",
"     53",
"    </a>",
"    ]. These are discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The yield of further genetic screening in such patients is low. This point is illustrated by the findings from a case series of 285 patients with clinical syndromes consistent with HD who were negative for the HTT mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/54\">",
"     54",
"    </a>",
"    ]. Additional screening for mutations associated with hereditary disorders that phenotypically resemble HD confirmed a genetic diagnosis in eight patients (3 percent), including seven with one of the Huntington disease-like syndromes and one with Friedreich ataxia.",
"   </p>",
"   <p>",
"    While any treating clinician can appropriately request molecular confirmation of a clinical diagnosis, the best care for these patients is managed by a multidisciplinary team that includes neurologists, psychiatrists, social workers, and genetic counselors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Presymptomatic genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our clinical experience, approximately 15 percent of individuals with a family history of HD wish to undergo testing to determine whether they carry the disease-causing HTT gene mutation. Common reasons for requesting testing include making decisions for child bearing, career and educational choices, or retirement planning.",
"   </p>",
"   <p>",
"    Presymptomatic testing should only be performed by specialists at a multidisciplinary clinic where pre-test guidance, test interpretation, and post-test psychological support can be provided regardless of test outcome. Patients should be informed that genetic testing does not allow one to determine the age of onset or other clinical factors because of the variability inherent in HTT gene expression.",
"   </p>",
"   <p>",
"    The combined risk of suicide, attempted suicide, and psychiatric hospitalization after predictive testing for HD is approximately 1 percent with appropriate support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/55\">",
"     55",
"    </a>",
"    ]. The risk is highest for those who are unemployed or have a prior psychiatric history. Persons who test negative for HD are also at an increased risk of depression.",
"   </p>",
"   <p>",
"    In patients who carry the disease-causing CAG expansion in the HTT gene, prenatal testing is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/56\">",
"     56",
"    </a>",
"    ], although rarely used.",
"   </p>",
"   <p>",
"    Despite increased understanding of the causes of age of onset, we do not recommend the use of family history or determination of CAG repeat length to make clinical predictions for individual patients, as these indicators are not sufficiently accurate for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/3\">",
"     3",
"    </a>",
"    ], particularly at the lower repeat sizes. This point is illustrated by finding that the time of disease onset for one pair of monozygotic twins differed by more than seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/57\">",
"     57",
"    </a>",
"    ]. A more complete understanding of influences on HD expression may allow us to predict age of onset more reliably in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of molecular testing, radiology is no longer used in confirming the diagnosis of HD. Nevertheless, neuroimaging studies can provide evidence supporting the diagnosis in patients with clinical features of HD. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Radiologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Brain MRI can also be useful in identifying an alternative diagnoses, such as ischemic infarction, pantothenate kinase-associated neurodegeneration, multiple sclerosis, neoplasm, or Creutzfeldt-Jakob disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for a patient with chorea who is atypical for HD, or is negative for the HTT mutation, is broad and consists of hereditary and acquired causes (",
"    <a class=\"graphic graphic_table graphicRef55794 \" href=\"mobipreview.htm?12/10/12462\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hereditary disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary causes of chorea range from benign familial chorea to degenerative disorders. It is the presence or absence of additional features that help in diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign hereditary chorea is a nonprogressive condition, with onset in infancy or early childhood. Occasionally, hypotonia and mild developmental delay can be seen. It is not associated with dementia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18058?source=see_link&amp;anchor=H24#H24\">",
"       \"Hyperkinetic movement disorders in children\", section on 'Benign hereditary chorea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Huntington disease-like 2 (HDL2) is a rare HD mimic caused by a trinucleotide expansion",
"      <span class=\"nowrap\">",
"       (CAG/CTG)",
"      </span>",
"      in the junctophilin-3 gene (JPH3) on chromosome 16q24.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/58\">",
"       58",
"      </a>",
"      ]. It has been reported mainly in patients of African ancestry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/59\">",
"       59",
"      </a>",
"      ], although it has also been found in a patient of apparent European ancestry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/60\">",
"       60",
"      </a>",
"      ]. Some of the cases of HDL2 have acanthocytosis, which is discussed below. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33833?source=see_link&amp;anchor=H4519438#H4519438\">",
"       \"Neuroacanthocytosis\", section on 'Huntington Disease-Like 2'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Occasionally, the spinocerebellar ataxias (SCA 1, 3, 17) may present with a Huntington disease-like phenotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"       \"The spinocerebellar ataxias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dentatorubral pallidoluysian atrophy (DRPLA) is a rare autosomal dominant disorder that typically presents in patients of Japanese origin with chorea, ataxia, and dementia. A variant of DRPLA, known as the Haw-River syndrome, has been reported in an African-American family. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link&amp;anchor=H16#H16\">",
"       \"The spinocerebellar ataxias\", section on 'Dentatorubral pallidoluysian atrophy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pantothenate kinase-associated neurodegeneration is a form of neurodegeneration with brain iron accumulation that typically presents with dystonia and basal ganglia iron deposition in children. It is an autosomal recessive disorder caused by mutations in the gene encoding pantothenate kinase 2 (PANK2). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"       \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuroferritinopathy is an autosomal dominant basal ganglia disease characterized by adult-onset of variable symptoms that include parkinsonism, chorea, and dystonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/62\">",
"       62",
"      </a>",
"      ]. The disorder is caused by mutations in the ferritin light chain gene.",
"     </li>",
"     <li>",
"      Neuroacanthocytosis is a group of disorders that can produce chorea and dementia. These features are accompanied by acanthocytes on peripheral blood smear. Additional manifestations may include neuropathy, seizures, self-mutilation, and oral-buccal-lingual dystonic movements. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33833?source=see_link\">",
"       \"Neuroacanthocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Friedreich ataxia is an autosomal recessive neurodegenerative disorder caused by mutations in the frataxin gene. The major clinical manifestations are neurologic dysfunction, cardiomyopathy, and diabetes mellitus. Almost all patients present with ataxia, and dysarthria is a common feature. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=see_link\">",
"       \"Friedreich ataxia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these hereditary diseases, DRPLA and HDL2 in particular are phenotypically indistinguishable from HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29832/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acquired disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired causes of chorea include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug and toxic exposure.",
"     </li>",
"     <li>",
"      Tardive dyskinesia, which is associated with drugs that block dopamine receptors (eg, antipsychotics and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ). Tardive dyskinesia tends to occur months or years after the initiation of treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link\">",
"       \"Tardive dyskinesia: Etiology and epidemiology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=see_link\">",
"       \"Tardive dyskinesia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sydenham chorea, which is associated with a history of rheumatic fever or streptococcal infection in childhood. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22007?source=see_link\">",
"       \"Sydenham chorea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Creutzfeldt-Jakob disease, which is a rapidly progressive dementing illness associated with ataxia and myoclonus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link\">",
"       \"Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/56/27521?source=see_link\">",
"       \"Patient information: Huntington disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease (HD) is an inherited progressive neurodegenerative disorder characterized by choreiform movements, dystonia, psychiatric problems, and dementia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated prevalence of HD is 5 to 8 per 100,000 population in Europe and North America, with a lower prevalence in non-European ethnic groups. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of HD begin insidiously with movement abnormalities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with psychiatric and cognitive features. Chorea is a key feature of HD, and the defining sign at the time of diagnosis. Psychiatric problems can include irritability, depression, dysphoria, agitation, apathy, anxiety, paranoia, delusions, and hallucinations. The dementia of HD is characterized by executive dysfunction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With disease progression, motor function slowly deteriorates. Chorea may eventually be replaced in advanced stages of HD by a parkinsonian akinetic-rigid state. The slow but relentless deterioration in cognitive and motor function causes significant morbidity and early mortality. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Advanced stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axial MRI images through the lateral ventricles demonstrate typical and prominent findings of caudate atrophy in late-stage HD. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HD is based upon presence of the typical clinical features, a family history of the disease, and confirmatory genetic testing for the disease-causing trinucleotide (CAG) repeat expansion in the HTT gene. Approximately one percent of patients with a typical HD phenotype test negative for the HTT gene mutation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for HD is broad and includes hereditary and acquired causes of chorea. Among the hereditary diseases, dentatorubral pallidoluysian atrophy and Huntington disease-like syndrome 2 (HDL2) are phenotypically indistinguishable from HD. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197400016\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Martin SuttonBrown, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/1\">",
"      Richards RI. Dynamic mutations: a decade of unstable expanded repeats in human genetic disease. Hum Mol Genet 2001; 10:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/2\">",
"      Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 2012; 27:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/3\">",
"      Brinkman RR, Mezei MM, Theilmann J, et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/4\">",
"      Maat-Kievit A, Losekoot M, Zwinderman K, et al. Predictability of age at onset in Huntington disease in the Dutch population. Medicine (Baltimore) 2002; 81:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/5\">",
"      Seneca S, Fagnart D, Keymolen K, et al. Early onset Huntington disease: a neuronal degeneration syndrome. Eur J Pediatr 2004; 163:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/6\">",
"      J&auml;hnel M. [The case of a 86-years old woman first diagnosed with Huntington's disease]. Psychiatr Prax 2004; 31 Suppl 1:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/7\">",
"      Blekher TM, Yee RD, Kirkwood SC, et al. Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res 2004; 44:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/8\">",
"      Lasker AG, Zee DS. Ocular motor abnormalities in Huntington's disease. Vision Res 1997; 37:3639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/9\">",
"      Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006; 67:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/10\">",
"      Starr A. A disorder of rapid eye movements in Huntington's chorea. Brain 1967; 90:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/11\">",
"      Leigh RJ, Newman SA, Folstein SE, et al. Abnormal ocular motor control in Huntington's disease. Neurology 1983; 33:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/12\">",
"      Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001; 58:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/13\">",
"      Di Maio L, Squitieri F, Napolitano G, et al. Onset symptoms in 510 patients with Huntington's disease. J Med Genet 1993; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/14\">",
"      Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001; 71:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/15\">",
"      Shiwach R. Psychopathology in Huntington's disease patients. Acta Psychiatr Scand 1994; 90:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/16\">",
"      Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996; 53:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/17\">",
"      Tsuang D, Almqvist EW, Lipe H, et al. Familial aggregation of psychotic symptoms in Huntington's disease. Am J Psychiatry 2000; 157:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/18\">",
"      Di Maio L, Squitieri F, Napolitano G, et al. Suicide risk in Huntington's disease. J Med Genet 1993; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/19\">",
"      Shiwach RS, Norbury CG. A controlled psychiatric study of individuals at risk for Huntington's disease. Br J Psychiatry 1994; 165:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/20\">",
"      Snowden J, Craufurd D, Griffiths H, et al. Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 2001; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/21\">",
"      Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 1993; 50:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/22\">",
"      Duff K, Paulsen J, Mills J, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010; 75:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/23\">",
"      Hamilton JM, Wolfson T, Peavy GM, et al. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry 2004; 75:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/24\">",
"      Aziz NA, van der Burg JM, Landwehrmeyer GB, et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008; 71:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/25\">",
"      Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust 1981; 1:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/26\">",
"      Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/27\">",
"      Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clin Genet 2000; 58:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/28\">",
"      Carella F, Scaioli V, Ciano C, et al. Adult onset myoclonic Huntington's disease. Mov Disord 1993; 8:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/29\">",
"      Kereshi S, Schlagenhauff RE, Richardson KS. Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings. Clin Electroencephalogr 1980; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/30\">",
"      Kirkwood SC, Siemers E, Stout JC, et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 1999; 56:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/31\">",
"      Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol 2006; 63:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/32\">",
"      Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006; 63:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/33\">",
"      Langbehn DR, Paulsen JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology 2007; 68:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/34\">",
"      Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/35\">",
"      Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/36\">",
"      Biglan KM, Ross CA, Langbehn DR, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009; 24:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/37\">",
"      Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010; 75:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/38\">",
"      Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/39\">",
"      Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011; 10:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/40\">",
"      Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004; 63:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/41\">",
"      Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001; 42:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/42\">",
"      Lee JK, Mathews K, Schlaggar B, et al. Measures of growth in children at risk for Huntington disease. Neurology 2012; 79:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/43\">",
"      Bamford KA, Caine ED, Kido DK, et al. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 1995; 45:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/44\">",
"      Young AB, Penney JB, Starosta-Rubinstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/45\">",
"      Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington's disease. Neuroreport 2002; 13:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/46\">",
"      Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/47\">",
"      Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005; 65:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/48\">",
"      Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008; 131:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/49\">",
"      Siesling S, Vegter-van de Vlis M, Losekoot M, et al. Family history and DNA analysis in patients with suspected Huntington's disease. J Neurol Neurosurg Psychiatry 2000; 69:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/50\">",
"      Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 2001; 60:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/51\">",
"      Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994; 330:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/52\">",
"      Andrew SE, Goldberg YP, Kremer B, et al. Huntington disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 1994; 54:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/53\">",
"      Wild EJ, Tabrizi SJ. Huntington's disease phenocopy syndromes. Curr Opin Neurol 2007; 20:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/54\">",
"      Wild EJ, Mudanohwo EE, Sweeney MG, et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/55\">",
"      Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999; 64:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/56\">",
"      Simpson SA, Harper PS, United Kingdom Huntington's Disease Prediction Consortium. Prenatal testing for Huntington's disease: experience within the UK 1994-1998. J Med Genet 2001; 38:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/57\">",
"      Friedman JH, Trieschmann ME, Myers RH, Fernandez HH. Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol 2005; 62:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/58\">",
"      Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004; 56:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/59\">",
"      Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007; 61:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/60\">",
"      Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008; 73:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/61\">",
"      Bauer P, Laccone F, Rolfs A, et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J Med Genet 2004; 41:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/62\">",
"      Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29832/abstract/63\">",
"      Walker FO. Huntington's disease. Lancet 2007; 369:218.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4907 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29832=[""].join("\n");
var outline_f29_8_29832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY/GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Motor symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Eye movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Weight loss and cachexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atypical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Juvenile Huntington disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advanced stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prediagnosis manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiologic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Presymptomatic genetic screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hereditary disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acquired disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197400016\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4907|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/1/18453\" title=\"diagnostic image 1\">",
"      MRI CT Huntington",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/42/7852\" title=\"table 1\">",
"      Symptoms Huntington disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/19/1339\" title=\"table 2\">",
"      Features juvenile HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/10/12462\" title=\"table 3\">",
"      Differential Dx Chorea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=related_link\">",
"      Huntington disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33833?source=related_link\">",
"      Neuroacanthocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/56/27521?source=related_link\">",
"      Patient information: Huntington disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22007?source=related_link\">",
"      Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29833="Cisplatin nephrotoxicity";
var content_f29_8_29833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cisplatin nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Didier Portilla, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     A Mazin Safar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Melissa L Shannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Richard T Penson, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29833/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/8/29833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in renal function, as manifested by a decline in the glomerular filtration rate (GFR), can be dose-limiting. The laboratory observation that forced hydration and diuresis may prevent nephrotoxicity facilitated the subsequent clinical development of cisplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -induced renal toxicity is reviewed here. The use of cisplatin in patients with preexisting renal dysfunction and the renal effects of the platinum analogs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mechanisms contribute to renal dysfunction following exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . These include tubular epithelial cell toxicity, vasoconstriction in the renal microvasculature, and proinflammatory effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cellular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is a potent cellular toxin, particularly in a low chloride environment. In the interior of cells, chloride atoms in cisplatin are replaced by water molecules. This hydrolysis product is believed to be the active species, reacting with glutathione in the cytoplasm and DNA in the nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/4\">",
"     4",
"    </a>",
"    ]. In tumors and other dividing cells, cisplatin-DNA intrastrand crosslinks result in cytotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/5\">",
"     5",
"    </a>",
"    ]. These molecular events are thought to be responsible for arresting cancer cell proliferation. More than 50 percent of the drug is excreted in the urine in the first 24 hours following cisplatin administration, and the concentration of platinum achieved in the renal cortex is several fold greater than that in plasma and other organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Cisplatin primarily injures the S3 segment of the proximal tubule, causing a decrease in the glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental studies suggest that basolateral drug transporters play a role in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/9\">",
"     9",
"    </a>",
"    ]. Changes in expression of proximal tubule organic cation transporter-2 (OCT2) have been shown to mediate the accumulation of cisplatin in proximal tubular epithelial cells, which suggests a key role for OCT2 in the development of cisplatin-mediated nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoconstriction in the renal microvasculature appears to contribute to decreased renal blood flow soon after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Proinflammatory effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    increases the expression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and caspases, which promote the differentiation, maturation, and activation of neutrophils, T cells, and other components of the cellular inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Experimental models of cisplatin-induced acute renal failure (ARF) demonstrate increased expression of endothelial cell adhesion molecules and subsequent infiltration of leukocytes and T cells in kidney tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The potential importance of these mediators was illustrated by the lesser severity of ARF following exposure to cisplatin in mice with defects in these inflammatory pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/15,16,20-22\">",
"     15,16,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects on the proximal tubule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal tubule cells are selectively injured by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , as manifested by both necrosis and apoptosis, even though nonproliferating cells are generally less sensitive to the toxicity of agents that damage DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible reasons for the observed nephrotoxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    include its enhanced renal uptake by organic transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/9\">",
"     9",
"    </a>",
"    ]. This is followed by cisplatin-mediated reduced expression and function of sodium-dependent glucose and amino acid transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/24\">",
"     24",
"    </a>",
"    ]; reduced expression and function of magnesium and water transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]; metabolism of cisplatin to glutathione and cysteinyl-glycine conjugates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/25\">",
"     25",
"    </a>",
"    ]; and the generation of reactive oxygen species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/26-32\">",
"     26-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cellular effects that have been proposed as the cause of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of mitochondrial F1F0-ATPase and reduction of mitochondrial oxidative phosphorylation and membrane potential, which are two intracellular events that precede cytochrome C release and apoptotic cell death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induction of hyperlipidemia and the accumulation of triglyceride and non-esterified fatty acids (NEFA) in kidney tissue, perhaps due to inhibition of fatty acid oxidation in the proximal tubule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Significant reduction in mRNA levels and enzyme activity of mitochondrial medium chain acyl-CoA dehydrogenase (MCAD).",
"     </li>",
"     <li>",
"      Possible direct inhibition of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity in renal epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. This may decrease the expression of PPAR-regulated genes, including those encoding potentially protective fatty acid binding proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important manifestation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity is renal impairment, which can be progressive. Other renal manifestations have been described, including hypomagnesemia, salt wasting, a Fanconi-like syndrome, and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of renal impairment varies, depending upon the dose and frequency of drug administration and the criteria used to define nephrotoxicity. Nephrotoxicity was observed in the initial phase I and phase II studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and was seen in more than 50 percent of cases in some of the early trials prior to the use of intensive hydration regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/1,39\">",
"     1,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence and severity of renal failure increases with subsequent courses and can eventually become irreversible. As a result, discontinuing therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is generally indicated in those who develop evidence of progressive renal impairment.",
"   </p>",
"   <p>",
"    These observations apply to the administration of conventional doses of platinum. Despite its potent antitumor activity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    cannot be used in the higher doses needed for bone marrow ablation prior to hematopoietic stem cell transplantation because of severe toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    , a less toxic analog, is often used in this setting.",
"   </p>",
"   <p>",
"    Unless the renal failure is advanced, the urine output in patients with nephrotoxicity typically remains above 1000 mL per day due to the induction of a concentrating defect. This defect may reflect platinum-induced damage to the loop of Henle, where the countercurrent gradient required for urinary concentration is established, or to the collecting tubules, the site of action of antidiuretic hormone&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/41\">",
"     41",
"    </a>",
"    ]. Injury to the collecting tubules is associated with decreased expression of aquaporin water channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    nephrotoxicity also appears to be mediated by the organic cation transporter (hOCT2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    may be associated with a different form of renal failure when given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , a thrombotic microangiopathy with features of the hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/44\">",
"     44",
"    </a>",
"    ]. A thrombotic microangiopathy has also been described when cisplatin is given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    . This disorder presumably reflects direct vascular injury with secondary platelet activation.",
"   </p>",
"   <p>",
"    The onset of renal failure may be abrupt or insidious; in the latter setting, it can develop months after treatment has been discontinued. The diagnosis of this form of nephrotoxicity is suggested by the concurrent presence of a microangiopathic hemolytic anemia and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypomagnesemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia due to urinary magnesium wasting occurs in over one-half of cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity and can be severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In addition to its direct clinical manifestations, hypomagnesemia may exacerbate cisplatin toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal subjects are able to make the urine virtually magnesium-free once the plasma magnesium concentration falls below 1.2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 0.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, a fractional excretion of magnesium (FEMg) above 2.5 percent is indicative of some component of magnesium wasting in the presence of hypomagnesemia. A review of magnesium handling and of the different units used to measure the plasma magnesium concentration os available in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fanconi-like syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -mediated nephrotoxicity is accompanied by the development of a Fanconi-like syndrome, with increased urinary excretion of glucose and amino acids (such as alanine, valine, leucine, methionine) and the presence of tricarboxylic acid (TCA) cycle metabolites (lactate and pyruvate) in the urine. In addition to being a marker of tubular damage, glucosuria may also occur due to cisplatin-induced glucose intolerance and hyperglycemia due to abnormal insulin and glucagon responses to a glucose stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/34,49-51\">",
"     34,49-51",
"    </a>",
"    ]. Classic Fanconi syndrome has not been reported, although mild tubular dysfunction may persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, nonspecific urinary markers of glomerular (high molecular weight proteins) and tubular toxicity (such as N-acetyl-beta-glucosaminidase [NAG]) are significantly elevated in acute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Salt wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically apparent renal salt wasting is a rare manifestation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity that has been described in case reports and small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is frequently associated with anemia that is out of proportion to its myelosuppressive effect on the other blood cell lines. Animal and human studies suggest that the renal tubular injury induced by cisplatin results in a deficiency of erythropoietin, which contributes to the anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with erythropoiesis-stimulating agents may be useful in this situation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ARF",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing risk of ARF is associated with higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    that result in high peak plasma free platinum concentrations, previous exposure to cisplatin, preexisting kidney damage, and the concomitant use of other nephrotoxic agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High peak plasma free platinum concentrations &mdash; High peak plasma free platinum concentrations are associated with an increased risk of ARF, which suggests that the cumulative dose of platinum may play a role in the development of nephrotoxicity. As an example, in a study of 22 patients receiving their first course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (50 to 140",
"      <span class=\"nowrap\">",
"       mg/m2),",
"      </span>",
"      the peak plasma concentration of free platinum correlated with glomerular toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/57\">",
"       57",
"      </a>",
"      ]. A peak plasma ultrafiltrable platinum level (free platinum level) in excess of 400",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      was associated with greater than 30 percent decline in creatinine clearance by the fourth course of therapy.",
"      <br/>",
"      <br/>",
"      Additional evidence supporting the importance of high peak plasma platinum concentrations comes from the observation that glomerular filtration rate (GFR) and serum magnesium levels were significantly decreased following cisplatin administration at doses &ge;50",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/58\">",
"       58",
"      </a>",
"      ]. By comparison, the GFR was maintained in patients receiving cisplatin at a lower daily dose of 20",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      over five consecutive days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Previous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      chemotherapy &mdash; Patients who are treated with salvage therapy after relapse following standard dose cisplatin-based first-line treatment are at increased risk for developing renal failure with additional cisplatin therapy. An increased risk of nephrotoxicity may also be observed when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , a less nephrotoxic platinum analog, is used instead of cisplatin in a salvage regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preexisting kidney damage &mdash; There is an increased risk of ARF with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      among patients with underlying kidney dysfunction, primarily due to the decreased renal clearance of cisplatin. Cisplatin-based chemotherapy is therefore considered contraindicated in patients with elevated serum creatinine levels.",
"      <br/>",
"      <br/>",
"      There are no definitive studies to help guide the threshold level of renal function at which cisplatin is not administered. In our centers, we make every effort to avoid using cisplatin among patients with a serum creatinine concentration greater than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [132.6",
"      <span class=\"nowrap\">",
"       &micro;mol/liter]",
"      </span>",
"      or an estimated glomerular filtration rate of less than 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Possible exceptions are situations in which cisplatin has a proven curative role, such as patients with testicular cancer. Many of the ongoing national clinical trials exclude patients with creatinine levels &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL[132.6",
"      </span>",
"      <span class=\"nowrap\">",
"       &micro;mol/liter]",
"      </span>",
"      from receiving cisplatin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concomitant administration of potentially nephrotoxic agents, such as aminoglycosides and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors are potentially associated with an increased risk of renal toxicity. In a study of 400 patients treated with weekly high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (70 to 85",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    risk factors included older age, female gender, smoking, hypoalbuminemia, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    co-administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The risk related to gender may be due in part to lower unbound cisplatin clearance in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approach to prevent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity is the administration of lower doses of cisplatin compared with previous regimens in combination with intravenous isotonic saline. Although a number of pharmacologic agents have been evaluated to decrease nephrotoxicity, none has an established role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lower doses of cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the spectrum of antitumor activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    has become better understood, newer chemotherapy regimens have been developed for palliative settings (eg, non-small cell lung cancer) that have facilitated the use of lower doses of cisplatin in conjunction with other newer chemotherapy agents. This approach has minimized the incidence of nephrotoxicity without lowering the therapeutic efficacy of cisplatin. In contrast, the doses of cisplatin are not lowered in settings in which cure is the goal of therapy (eg, small cell lung and testicular germ cell tumors).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intravenous saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to accurately characterize the effectiveness of intravenous saline in preventing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity. This is because, among the trials that have evaluated cisplatin, there were varying definitions of nephrotoxicity, variable cisplatin doses, and patient populations that differed by comorbidity and underlying malignancy.",
"   </p>",
"   <p>",
"    In general, the administration of intravenous saline with the resultant diuresis significantly lowers the risk of nephrotoxicity. In the initial phase I and II studies, nephrotoxicity was observed in more than 50 percent of cases administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. It was subsequently observed that the induction of a diuresis using the administration of intravenous saline dramatically lowered the incidence of nephrotoxicity to very low levels (zero percent in some small uncontrolled series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/63\">",
"     63",
"    </a>",
"    ]. This allowed the development of cisplatin for clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of intravenous saline to induce a diuresis remains the primary approach for preventing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity and must be used in all patients treated with cisplatin. The optimal hydration solution and regimen to prevent nephrotoxicity associated with cisplatin administration is unclear. There are no studies that have compared different regimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    types of intravenous fluids in prospective randomized studies.",
"   </p>",
"   <p>",
"    We prepare a solution consisting of 1000 mL of isotonic saline plus 20 mEq of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    and 2 grams of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    . We administer intravenously a minimum of 1000 mL of this solution over two to three hours prior to and a minimum of 500 mL over the two hours following the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    administration. This fluid administration should be adequate to establish a urine flow of at least 100",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for two hours prior to and two hours after chemotherapy administration. Among patients in whom this regimen is contraindicated, alternate chemotherapeutic regimens that do NOT include cisplatin should be considered.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    is frequently used to induce diuresis, although there is no evidence that this is required. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    is generally not required, unless there is evidence of fluid overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cisplatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The less nephrotoxic analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    has been substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in many chemotherapy regimens (eg, ovarian cancer, non-small cell lung cancer). The relative activity of cisplatin and carboplatin in different diseases needs to be considered in determining whether or not this is a feasible approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    , an organic thiophosphate, may protect against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced toxicity by donating a protective thiol group, an effect that is highly selective for normal, but not malignant, tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/64\">",
"     64",
"    </a>",
"    ]. Treatment with amifostine prior to cisplatin administration decreased nephrotoxicity in animal models and preliminary clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III trial in women with ovarian cancer found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    reduced the incidence of nephrotoxicity (&ge;40 percent reduction in creatinine clearance) from 33 to 10 percent with six cycles of a chemotherapy regimen that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of these results, the 2002 guidelines from the American Society of Clinical Oncology stated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    could be considered in patients receiving repeated administrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for ovarian or non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/66\">",
"     66",
"    </a>",
"    ], a position that was reiterated in the updated 2008 guidelines, with no new data on which to base a change in the recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/67\">",
"     67",
"    </a>",
"    ]. However, these studies used higher doses of cisplatin than are typical of contemporary regimens (which almost all use either a single bolus dose of 75 to 80",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    or, in the setting of a germ cell tumor, a split dose of 20",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    daily for five days), and there are no data supporting the use of amifostine in other settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do NOT use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    to prevent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity. The principal reasons include the availability of newer regimens that use lower doses of cisplatin or substitute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for cisplatin, and the significant toxicity (nausea, vomiting, hypotension) and costs associated with the administration of amifostine. Furthermore, concerns persist about possible interference with the antitumor efficacy of cisplatin. Amifostine should not be used in settings in which chemotherapy can produce a significant survival advantage or chance of cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other chemopreventive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other approaches have been evaluated to prevent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity. None of the following agents have an established role in patients being treated with cisplatin:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sodium thiosulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intraperitoneal tumors may be treated with intraperitoneal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    to achieve high local drug levels and relatively low plasma concentrations. In this setting, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    was given concurrently to bind covalently with the platinum that enters the systemic circulation. The resulting complex has no systemic or renal toxicity and also has no antitumor effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other thiols, such as N-acetylcysteine (NAC), were evaluated for primary prophylaxis and may have some role in preventing platinum nephrotoxicity in high-risk patients. Thiols are thought to act both on the death receptor and the mitochondrial apoptotic pathways that are induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    was suggested by a study in rats, in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    prevented",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/71\">",
"     71",
"    </a>",
"    ]. In an exploratory clinical trial, 41 patients were randomly assigned to receive theophylline or placebo, in conjunction with chemotherapy that included one dose of cisplatin (50",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients treated with theophylline had no change in GFR, while a significant decrease was observed in those receiving placebo (92.9 versus 71.8",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Additional clinical studies will be required to confirm these observations, particularly when patients receive higher doses of cisplatin and multiple cycles of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Glycine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -induced nephrotoxicity has been minimized in experimental models by the administration of glycine, but not other amino acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/73\">",
"     73",
"    </a>",
"    ], and a peroxisome proliferator-activated alpha ligand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/34\">",
"     34",
"    </a>",
"    ]. Complementary and alternative agents, such as milk thistle and the flavonoid antioxidant quercetin, have shown some protective effects in laboratory models of cisplatin-induced nephrotoxicity. The clinical utility of these agents remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H554610594\">",
"    <span class=\"h3\">",
"     Polymeric cisplatin nanoparticles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymeric",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nanoparticles that target the endolysosomal compartment of cancer cells may limit nephrotoxicity, but their clinical utility has not been shown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     General approach to renal dysfunction or failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approaches to the management of acute renal dysfunction and renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Supportive management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Discontinuation of cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    should be discontinued in the presence of acute kidney injury, which is currently defined as an increase in the serum creatinine concentration of &ge;50 percent over baseline levels or a reduction in urine output &lt;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for greater than six hours. Timely discontinuation of cisplatin may prevent progressive renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hypomagnesemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypomagnesemia generally consists of magnesium supplementation. High doses may be required since raising the plasma magnesium concentration will increase the degree of urinary magnesium wasting. The treatment of hypomagnesemia is discussed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific treatment of thrombotic microangiopathy resulting from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and other chemotherapeutic agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Drug-induced TTP-HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up of patients exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    indicates that renal function either remains stable or improves over time in patients with a GFR greater than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 at the end of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Whether such improvement reflects an increase in the number of functioning nephrons, or hypertrophy of nephrons that remained relatively intact is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29833/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    is a potent anti-tumor agent usually administered in combination with other chemotherapy agents to treat a broad spectrum of malignancies. Cisplatin-induced nephrotoxicity is a dose-limiting side effect, which most commonly is manifested by acute and chronic impairment of renal function. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The likelihood of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced nephrotoxicity is increased with high peak plasma free platinum concentrations, previous therapy with cisplatin, underlying chronic kidney disease, and concomitant use of other nephrotoxic agents. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of measures are potentially useful to prevent acute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity and chronic renal impairment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend intravenous isotonic saline to induce a diuresis before and after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      administration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Intravenous saline'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The optimal intravenous solution and regimen is unclear. We prepare a solution consisting of 1000 mL of isotonic saline plus 20 mEq of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      and 2 grams of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      . Although there is no standard approach, we administer intravenously a minimum of 1000 mL of this solution over the two to three hours prior to and 500 mL over the two hours following the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      administration to maintain a urine flow of at least 100",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for two hours before and two hours after drug administration. Among patients in whom this regimen is contraindicated, therapeutic regimens that do NOT include cisplatin should be encouraged.",
"     </li>",
"     <li>",
"      There is no evidence that the use of chemopreventive agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      is clinically useful in preventing nephrotoxicity in patients being treated with contemporary",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      in most patients with underlying renal disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Possible exceptions are situations in which cisplatin has a proven curative role, such as patients with testicular cancer. We recommend avoiding the coadministration of other potentially nephrotoxic agents, such as aminoglycosides, nonsteroidal antiinflammatory agents, or iodinated contrast media (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Risk factors for ARF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      is contraindicated or in whom there is an increased risk of nephrotoxicity, the substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      for cisplatin can be considered. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal impairment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/1\">",
"      Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/2\">",
"      Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/3\">",
"      Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/4\">",
"      Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/5\">",
"      Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta 2002; 1579:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/6\">",
"      Litterst, CL, Torres, IJ, Guarino, AM, et al. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP (II). J Clin Hematol Oncol 1977; 7:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/7\">",
"      Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984; 25:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/8\">",
"      Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/9\">",
"      Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998; 287:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/10\">",
"      Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/11\">",
"      Filipski, K, Loops, WJ, Verweij, J, et al. Interaction of cisplatin with human organic cation transporter OCT2 Clin Pharmacol Ther 2008; 83(Suppl 1):S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/12\">",
"      Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/13\">",
"      Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/14\">",
"      Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985; 249:F490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/15\">",
"      Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/16\">",
"      Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289:F166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/17\">",
"      Kelly KJ, Meehan SM, Colvin RB, et al. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int 1999; 56:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/18\">",
"      Li S, Gokden N, Okusa MD, et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:F469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/19\">",
"      Liu M, Chien CC, Burne-Taney M, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 2006; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/20\">",
"      Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285:F610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/21\">",
"      Faubel S, Ljubanovic D, Reznikov L, et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004; 66:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/22\">",
"      Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72:37.",
"     </a>",
"    </li>",
"    <li>",
"     Portilla, D, Kaushal, GP, Basnakian, AG. Recent Progress in the Pathophysiology of Acute Renal Failure. In: Principles of Molecular Medicine, 2nd ed, Runge, MS, and Patterson, C (Eds), Humana Press, Inc, Totawa, NJ 2006. pp. 643-649.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/24\">",
"      Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem Res Toxicol 2008; 21:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/25\">",
"      Townsend DM, Deng M, Zhang L, et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/26\">",
"      Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/27\">",
"      Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001; 12:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/28\">",
"      Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/29\">",
"      Tanaka-Kagawa T, Kitahara J, Seko Y, et al. Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. Biochem Pharmacol 1999; 57:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/30\">",
"      Appenroth D, Fr&ouml;b S, Kersten L, et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997; 71:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/31\">",
"      Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270:F700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/32\">",
"      McGinness JE, Proctor PH, Demopoulos HB, et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys 1978; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/33\">",
"      Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 2002; 277:43377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/34\">",
"      Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006; 69:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/35\">",
"      Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 1999; 18:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/36\">",
"      Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286:F572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/37\">",
"      Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/38\">",
"      Negishi K, Noiri E, Sugaya T, et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007; 72:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/39\">",
"      Wittes RE, Brescia F, Young CW, et al. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975; 32:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/40\">",
"      Vasey PA. \"Dose dense\" chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15 Suppl 3:226.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 120-135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/42\">",
"      Kim SW, Lee JU, Nah MY, et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001; 12:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/43\">",
"      Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/44\">",
"      Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/45\">",
"      Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/46\">",
"      Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 1986; 8:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/47\">",
"      Sutton RA, Walker VR, Halabe A, et al. Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 1991; 117:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/48\">",
"      Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/49\">",
"      Goldstein RS, Mayor GH, Rosenbaum RW, et al. Glucose intolerance following cis-platinum treatment in rats. Toxicology 1982; 24:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/50\">",
"      Goldstein RS, Mayor GH, Gingerich RL, et al. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 1983; 69:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/51\">",
"      Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/52\">",
"      Koch Nogueira PC, Hadj-A&iuml;ssa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998; 12:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/53\">",
"      Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/54\">",
"      Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin. Ann Intern Med 1988; 108:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/55\">",
"      Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol 2002; 25:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/56\">",
"      Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/57\">",
"      Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/58\">",
"      Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/59\">",
"      Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/60\">",
"      Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/61\">",
"      de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/62\">",
"      de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/63\">",
"      Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/64\">",
"      Castiglione F, Dalla Mola A, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999; 85:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/65\">",
"      Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/66\">",
"      Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/67\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/68\">",
"      Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/69\">",
"      Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/70\">",
"      Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005; 312:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/71\">",
"      Heidemann HT, M&uuml;ller S, Mertins L, et al. Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol 1989; 97:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/72\">",
"      Benoehr P, Krueth P, Bokemeyer C, et al. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 2005; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/73\">",
"      Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int 1993; 43:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/74\">",
"      Sengupta P, Basu S, Soni S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012; 109:11294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/75\">",
"      Bundy JT, Connito D, Mahoney MD, Pontier PJ. Treatment of idiopathic renal magnesium wasting with amiloride. Am J Nephrol 1995; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/76\">",
"      Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/77\">",
"      Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991; 118:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/78\">",
"      Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29833/abstract/79\">",
"      Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249:F324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7231 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29833=[""].join("\n");
var outline_f29_8_29833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cellular toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Proinflammatory effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects on the proximal tubule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fanconi-like syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Salt wasting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISK FACTORS FOR ARF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lower doses of cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intravenous saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cisplatin analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Amifostine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other chemopreventive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sodium thiosulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Theophylline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Glycine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H554610594\">",
"      - Polymeric cisplatin nanoparticles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      General approach to renal dysfunction or failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Discontinuation of cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29834="Tunneled, cuffed hemodialysis catheter-related bacteremia";
var content_f29_8_29834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tunneled, cuffed hemodialysis catheter-related bacteremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Michael Allon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/8/29834/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/8/29834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters, originally introduced as vascular access for short-term dialysis, have become an acceptable form of permanent vascular access. Both non-tunneled, non-cuffed catheters and tunneled, cuffed catheters are available. At present, tunneled, cuffed, double-lumen silastic catheters are the preferred access for short- and intermediate-term use in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/1\">",
"     1",
"    </a>",
"    ]. These catheters are also used for permanent vascular access in some patients, particularly those with limited alternative options for vascular access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To a significant degree, the transition from non-tunneled catheters to tunneled, cuffed catheters has been driven by a change in preference for AV fistulas rather than AV grafts. Because fistulas require a much longer maturation time than grafts, the duration of catheter-dependence for vascular access has increased substantially in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, a catheter is used for the initial dialysis session in approximately 80 percent of incident hemodialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tunneled, cuffed catheters are associated with a number of complications, particularly catheter-related bacteremia. The clinical impact of catheter-related bacteremia in hemodialysis patients has been quantified in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In the HEMO study, for example, 7.6 percent of all patients had catheters used for vascular access, yet this group comprised 32 percent of all study patients hospitalized with access-related infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of tunneled, cuffed dialysis catheter-related bacteremia is presented in this topic review. Other catheter-related complications, such as thrombosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Catheter-related bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of bacteremias in hemodialysis patients are caused by infection of vascular access catheters. The incidence of bacteremia is greater in patients with indwelling tunneled catheters than in those with either fistulas or synthetic grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The relative risk of tunneled dialysis catheters causing bacteremia in dialysis patients has been estimated to be approximately 10 times higher than the risk of bacteremia in patients with AV fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, catheter-dependent hemodialysis patients have a two- to threefold higher risk of infection-related hospitalization and infection-related death, as compared to patients undergoing dialysis via a fistula or graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of catheter-related bacteremia in several large case series has ranged between 2.5 and 5.5 episodes per 1000 catheter-days, which corresponds to an incidence of 0.9 to 2 episodes of bacteremia per catheter-year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"     11",
"    </a>",
"    ]. In one prospective study involving 108 tunneled catheter-dependent hemodialysis patients, the cumulative likelihood of catheter-related bacteremia was 35 percent within three months and 48 percent within six months of catheter insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of improvements in design, the frequency of catheter-related bacteremia is now relatively less in patients with tunneled versus non-tunneled catheters. The frequency of catheter-related bacteremia was two- to threefold lower in patients with tunneled dialysis catheters, in two large observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Metastatic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis catheter-related bacteremia may also be associated with metastatic complications, such as osteomyelitis, endocarditis, septic arthritis, or epidural abscess. Metastatic infections have been observed in about 5 to 10 percent of catheter-dependent hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"     11",
"    </a>",
"    ]. The increased frequency of the use of catheters has in turn led to an increasing incidence of such metastatic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of metastatic infection varies with the type of infecting pathogen. In general, serious metastatic infections occur more frequently in patients with infections due to Staphylococcus aureus. The reported incidence with S. aureus ranges from 10 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It is important to note that such metastatic infections may not be immediately obvious as their onset can sometimes occur weeks or even sometimes months after the initial bacteremic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis catheter-related bacteremia can arise from one of two sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migration from the skin along the outside of the catheter into the bloodstream. The Dacron cuff in tunneled catheters typically incites an inflammatory response with fibrosis, that in turn and in time may create a mechanical barrier to migration of bacteria from the skin along the outside of the catheter.",
"     </li>",
"     <li>",
"      Direct inoculation from a biofilm containing pathogenic microorganisms that may form on the inner surface of the catheter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for tunneled catheter-related bacteremia is prolonged duration of usage. As previously noted, the cumulative likelihood of catheter-related bacteremia in one study was 35 and 48 percent within three and six months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors for bacteremia include a history of previous catheter-related bacteremia, recent surgery, diabetes mellitus, iron overload, immunosuppression, and hypoalbuminemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11,17-19\">",
"     11,17-19",
"    </a>",
"    ]. However, rather surprisingly, HIV infection has not been associated with a higher risk of catheter-related bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-positive organisms are responsible for most dialysis catheter-related infections. Coagulase-negative staphylococcal and S. aureus together account for 40 to 80 percent of cases in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11,15,21-25\">",
"     11,15,21-25",
"    </a>",
"    ]. S. aureus infection is commonly associated with significant morbidity and mortality, as shown in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study of 22,130 hospitalizations of dialysis patients with septicemia, the overall death rate from S. aureus bacteremia after 12 weeks of follow-up was 34 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/3\">",
"       3",
"      </a>",
"      ]. The death rate was 20 percent higher than the death rate from bacteremia due to all other organisms.",
"     </li>",
"     <li>",
"      In another study, 21 percent of 11,572 admissions of hemodialysis patients for S. aureus bacteremia had one or more complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/4\">",
"       4",
"      </a>",
"      ]. The average length of first hospitalization was 13 days, and 12 percent of these 11,572 patients were readmitted within 12 weeks for treatment of a relapsed infection.",
"     </li>",
"     <li>",
"      In another report, the unadjusted 12 week mortality for dialysis catheter-related S. aureus bacteremia was 23 percent among patients with S. aureus bacteremia due to a dialysis catheter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methicillin-resistant S. aureus infection (MRSA) has also become an important pathogen in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Hemodialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-staphylococcal dialysis catheter-associated bacteremias are due predominantly to enterococci and Gram-negative rods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11,15,21-24,27,28\">",
"     11,15,21-24,27,28",
"    </a>",
"    ]. HIV-positive dialysis patients are more likely to develop polymicrobial infections and infections due to Gram-negative and fungal pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. Gram-negative organisms accounted for 30 to 40 percent of all episodes of catheter-related bacteremia, and 10 to 20 percent of episodes were polymicrobial in several case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonspecific, fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chills are the most sensitive clinical manifestations of catheter-induced bacteremia. In three prospective clinical studies, the presence of fever or chills in catheter-dependent hemodialysis patients was associated with positive blood cultures in approximately 60 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. By comparison, purulence at the insertion site or an exit-site infection is more specific but less sensitive. It is important to note that the great majority of cases of catheter-associated bacteremia occur in the absence of evidence of an exit-site infection. In a series of 1436 episodes of tunneled dialysis catheter-associated bacteremias, a concurrent purulent exit site infection was observed in only 4.6 percent of cases, including 9.6 percent of those with a Staphylococcus epidermidis infection, 6.1 percent of those with a Staphylococcus aureus infection, and &lt;1 percent of these with a gram-negative infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common clinical manifestations may include hemodynamic instability, altered mental status, catheter dysfunction, and other symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of sepsis, such as hypothermia, acidosis, and hypotension. Complications related to a bloodstream infection, such as suppurative thrombophlebitis, endocarditis, septic arthritis, osteomyelitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abscess, may also be the first clues to the presence of catheter-related bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-induced bacteremia should be suspected in any dialysis patient with a hemodialysis catheter and signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of a bloodstream infection, particularly when there is no clinical evidence for an alternate source of infection. Whenever bacteremia is suspected, two blood cultures should be drawn, which can consist of a single peripheral drawn blood sample and a second sample obtained from the dialysis catheter or two samples drawn from separate peripheral sites. However, if blood cannot be obtained from a peripheral vein, two separate samples drawn 10 to 15 minutes apart from the dialysis catheter or dialysis tubing should be obtained before antibiotics are administered.",
"   </p>",
"   <p>",
"    Initial evaluation to exclude other possible causes of the presenting symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs is highly variable, and such testing, in large part, depends upon the individual symptoms and the clinical setting. In general, a basic history and physical examination is the starting point; additional laboratory and radiologic evaluation will depend upon the results of this evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive diagnosis of catheter-induced bacteremia requires one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent positive blood cultures of the same organism from the catheter and a peripheral vein, with the colony count or differential time to positivity meeting certain criteria.",
"     </li>",
"     <li>",
"      Culture of the same organism from both the catheter tip and at least one percutaneous blood culture.",
"     </li>",
"     <li>",
"      Cultures of the same organism from two peripherally drawn blood cultures and an absence of an alternate focus of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Meeting these criteria is relatively straightforward in nondialysis hospitalized patients. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these criteria are difficult to satisfy among many hemodialysis patients. This is particularly true in those undergoing maintenance dialysis as outpatients, a setting in which the vast majority of cases of catheter-induced bacteremia are first suspected. The ability to obtain cultures from peripheral blood is particularly difficult in this setting. Thus, among dialysis patients in whom a peripheral blood sample cannot be obtained, catheter-induced bacteremia can be diagnosed if TWO cultures drawn at separate times (10 to 15 minutes) from blood tubing are positive with a credible pathogen in a patient with sign and symptoms of bacteremia, but without evidence of an alternate source of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic difficulties among dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations with classic diagnostic criteria for catheter-induced bacteremia among dialysis outpatients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining peripheral blood cultures may not be possible in up to 40 percent of dialysis patients, either because their peripheral veins cannot be accessed or because an existing vein needs to be preserved for future fistula or graft creation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11,33,34\">",
"       11,33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs occur during a dialysis session, it is unlikely that there is a meaningful difference between samples drawn from peripheral veins and those drawn from catheters or dialysis tubing since systemic blood is circulating through the dialysis system.",
"     </li>",
"     <li>",
"      Handling of blood cultures obtained in the outpatient dialysis setting is frequently less than ideal. Limitations include a variable period before culture bottles are eventually placed in an incubator and differences in temperature during transport to a microbiology laboratory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of catheter-related bacteremia is broad. It includes alternate causes of fever, chills, hemodynamic instability, changes in mental status, catheter dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia. It is particularly important to consider sources of bacteremia other than the dialysis catheter, including pneumonia, foot infection, and others.",
"   </p>",
"   <p>",
"    The causes of such symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs may also vary based upon when they occur. As an example, the causes of hemodynamic instability in a hemodialysis patient may differ if these signs occur during a hemodialysis session then when similar signs are observed outside of such a session. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of dialysis catheter-induced bacteremia involves systemic antibiotic therapy and issues surrounding removal of the cuffed dialysis catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric systemic antimicrobial therapy is administered to all dialysis patients suspected of having dialysis catheter-induced bacteremia. In general, empiric antibiotic therapy is instituted after cultures are submitted and before culture and susceptibility results are available. Subsequent therapy should be tailored to microbiology results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Empiric treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, catheter-related bacteremia may result from a broad array of Gram-positive and Gram-negative organisms. In many dialysis centers in the United States, Staphylococcal infections are also frequently methicillin-resistant.",
"   </p>",
"   <p>",
"    Thus, the empiric treatment of dialysis patients suspected of having a vascular access infection initially involves the administration of broad-spectrum antibiotics to cover both Gram-positive and Gram-negative organisms. Antibiotics are also routinely selected on the basis of pharmacokinetics properties that permit or facilitate dosing with",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after each dialysis session.",
"   </p>",
"   <p>",
"    Among dialysis patients suspected of having a vascular access infection, we suggest the following regimen for empiric systemic antimicrobial therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      is administered for Gram-positive coverage until sensitivities become available.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      may be substituted for vancomycin for patients who have a documented vancomycin allergy.",
"     </li>",
"     <li>",
"      Broad-spectrum Gram-negative coverage can be provided with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      . The pharmacokinetics properties of both agents are compatible with their administration thrice weekly after each dialysis session. Since the frequency of aminoglycoside ototoxicity may be quite high (up to 20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/35\">",
"       35",
"      </a>",
"      ], some experts feel that ceftazidime is a better choice than gentamicin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/33\">",
"       33",
"      </a>",
"      ]. Other experts, however, prefer gentamicin since ceftazidime resistance is observed in some institutions, and less toxic treatment with a non-aminoglycoside can be used when cultures return and better alternatives can be chosen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus EITHER",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    include a broad spectrum of coverage for Gram-positive and Gram-negative pathogens and relative ease of administration in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/1\">",
"     1",
"    </a>",
"    ]. The following are usual doses for patients undergoing maintenance hemodialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , in a dose of 20",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      should be given as a loading dose during the last 60 minutes of the dialysis session, followed by 500 mg in the last 30 to 60 minutes of subsequent dialysis sessions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Vancomycin may be administered immediately after a dialysis session in inpatients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      , in a dose of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      should be given after each hemodialysis session. To prevent underdosing and an increased risk of ototoxicity, the dose should be based on ideal body weight, rather than actual weight. In addition, some experts do not administer more than 100 mg per dose. Care must be used when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and gentamicin are used in combination because of the risk of ototoxicity. This risk, particularly with aminoglycosides, cannot be overstated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, it is important to ensure that adequate doses are given as there is a near linear relationship between dose and ideal body weight in terms of achieving target serum levels. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link\">",
"       \"Aminoglycosides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , 2 gm, should be given after each hemodialysis session.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For outpatient dialysis patients who are allergic to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    may be administered at a dose of 9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (for patients using high-permeability dialyzers) or 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (for patients using low-permeability dialyzers) during the last 30 minutes of each dialysis session [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/38\">",
"     38",
"    </a>",
"    ]. For inpatients, daptomycin should be administered at a dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    after a dialysis session has finished.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stopping empiric therapy &mdash; Among patients suspected of having hemodialysis catheter-related bacteremia, empiric systemic antimicrobial therapy can be stopped if both sets of initial blood cultures have negative results and there is no other identified source of infection and signs and symptoms of bacteremia have resolved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tailored treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the organism and sensitivity have been identified, the antibiotic regimen should be modified accordingly. Again, an important factor in choosing an antibiotic is the ability to administer the antimicrobial with",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after each dialysis session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89483362\">",
"    <span class=\"h4\">",
"     Methicillin-resistant staphylococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the isolation of a methicillin-resistant Staphylococcus, we continue to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    if the organism has a low-minimal inhibitory concentration. Patients with vancomycin allergy can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The treatment of methicillin-resistant Staphylococcus, including issues related to minimal inhibitory concentration, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89483369\">",
"    <span class=\"h4\">",
"     Methicillin-sensitive staphylococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a Staphylococcal infection is established to be methicillin-sensitive,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be substituted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (a first-generation cephalosporin) in patients who are not allergic to these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/39\">",
"     39",
"    </a>",
"    ]. Conversion to cefazolin at an intravenous dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    after each dialysis session has become our clinical practice when susceptible organisms are isolated from blood cultures and the patient is not allergic to beta-lactams. Vancomycin is the preferred treatment for patients who are penicillin-allergic.",
"   </p>",
"   <p>",
"    Our preference for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    in this setting is due in part to the observation that the widespread use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    has been associated with an increasing incidence of infections due to vancomycin-resistant enterococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, cefazolin is as or more effective than vancomycin for treatment of methicillin-sensitive staphylococcal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      monotherapy as initial antibiotic treatment in 15 consecutive hemodialysis patients in whom intravenous antibiotic therapy was indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/41\">",
"       41",
"      </a>",
"      ]. Most infections were due to an infected access. All patients were treated with 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of cefazolin (rounded to the nearest 500 mg with doses ranging from 1 to 2 g), which was administered after each dialysis treatment for a minimum of three doses. At three weeks, resolution of the infection was observed in all patients. Despite the utilization of high-flux, high-efficiency, and conventional hemodialysis in this population, the serum concentrations of the drug predialysis exceeded the minimum inhibitory concentration in all patients.",
"     </li>",
"     <li>",
"      A prospective observational study evaluated 123 hemodialysis patients (55 percent with a cuffed catheter) with methicillin-susceptible Staphylococcus aureus bacteremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/39\">",
"       39",
"      </a>",
"      ]. All patients received an initial loading dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      Once the culture results were available, the patients were treated after each dialysis treatment with either vancomycin (500 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (2 g if the next dialysis session was in two days or 3 g if the next dialysis session was in three days). Treatment failure, defined as death or recurrent infection at 12 weeks after the initial positive blood culture, was more common with vancomycin (31 versus 13 percent with cefazolin, adjusted odds ratio 3.5, 95% CI 1.2-13.4) and with retention of the vascular access (adjusted odds ratio 5, 95% CI 1.9-13.8).",
"     </li>",
"     <li>",
"      A retrospective study analyzed data from 3844 chronic hemodialysis patients with methicillin sensitive S. aureus bacteremia (61 to 67 percent with catheters) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/43\">",
"       43",
"      </a>",
"      ]. One week after blood culture results were available, 56.1 and 16.7 percent of outpatients were receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , respectively. Among outpatients, cefazolin use was associated with lower risk of hospitalization or death (adjusted hazard ratio 0.62, 95% CI 0.46-0.84).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89483383\">",
"    <span class=\"h4\">",
"     Vancomycin-resistant enterococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -resistant enterococcus can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/38\">",
"     38",
"    </a>",
"    ]. Daptomycin should be administered at a dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    when it is infused following a dialysis session in inpatients. However, daptomycin should be administered to outpatient dialysis patients at a dose of 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (for patients using low-flux dialyzers) or 9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (for patients using high-flux dialyzers) during the last 30 minutes of each dialysis session [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/38\">",
"     38",
"    </a>",
"    ]. This higher dose is required to compensate for intra-dialytic daptomycin removal and ensure therapeutic plasma concentrations to minimize treatment failures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89483397\">",
"    <span class=\"h4\">",
"     Gram-negative organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many institutions, up to 95 percent of Gram-negative bacteria isolated in dialysis catheter-related bacteremia are presently sensitive to both aminoglycosides and third-generation cephalosporins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. As previously mentioned, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    for longer-term treatment rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    given the risk of aminoglycoside ototoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in regions or institutions in which resistance to ceftazidime is more common, aminoglycosides or drugs such as carbapenems may be alternate choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89483390\">",
"    <span class=\"h4\">",
"     Candidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The isolation of candida requires catheter removal and treatment with an appropriate antimicrobial agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/30\">",
"     30",
"    </a>",
"    ]. The reasons for the requirement for catheter removal are presented below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Guidewire catheter exchange'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With respect to appropriate antimicrobial therapy, the choice of agent involves sensitivity and speciation of the organism and other issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Monitoring issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all patients with initially positive blood cultures, it is our practice to repeat blood cultures 48 to 96 hours after the institution of treatment. If these repeat blood cultures remain positive, catheter removal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional evaluation for a metastatic infection or endocarditis may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum antibiotic levels are measured infrequently in hemodialysis patients. This is due to a variety of reasons, including delays in obtaining laboratory results, uncertainty concerning appropriate serum levels, and wide variations in clearance of antibiotics with dialysis. However, in an attempt to ensure that therapeutic levels are achieved, we obtain drug levels one hour after the dose is given in all hemodialysis patients receiving aminoglycosides for more than 48 to 72 hours. This issue and target therapeutic levels are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also obtain echocardiograms in all patients with prolonged S. aureus bacteremia. This is defined as positive S. aureus blood cultures that occur after 48 to 72 hours of therapy. It is also important to evaluate such patients for signs and symptoms of a metastatic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antimicrobial therapy remains uncertain. The length of therapy depends upon the infecting organism and whether the catheter is removed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients in whom the infected catheter has been removed and replaced with a new catheter, and in whom all signs of infection rapidly resolve and in whom follow-up blood cultures are negative, we treat uncomplicated catheter-related bacteremia for two to three weeks.",
"     </li>",
"     <li>",
"      Among patients in whom the infected catheter has been treated with an antibiotic lock solution, we treat uncomplicated catheter-related bacteremia for two to three weeks.",
"     </li>",
"     <li>",
"      We treat uncomplicated catheter-related bacteremia due to S. aureus for four weeks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=see_link\">",
"       \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is evidence of a metastatic infection or when blood cultures remain positive after three or more days of appropriate therapy, we advise at least six weeks of therapy.",
"     </li>",
"     <li>",
"      Among patients with osteomyelitis, we advise treatment for six to eight weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We re-culture until we are sure that the original bacteremia has been proven to be resolved. Some experts also recommend repeating blood cultures one week after completion of antibiotic therapy to ensure that a relapse of bacteremia has not occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Catheter management",
"    </span>",
"    &nbsp;&mdash;&nbsp;With dialysis catheter-induced bacteremia, the optimal management approach to the tunneled cuffed catheter is difficult since the catheter is both the source of the infection and the vascular access necessary for providing ongoing dialysis.",
"   </p>",
"   <p>",
"    All patients with dialysis catheter-induced bacteremia are administered systemic antimicrobial therapy. In addition to such therapy, the principal options concerning catheter management are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate catheter removal followed by placement of a temporary non-tunneled catheter for short-term dialysis access. After bacteremia has resolved, a new, tunneled dialysis catheter can be inserted.",
"     </li>",
"     <li>",
"      Replacement of the infected catheter via exchange over a guidewire",
"     </li>",
"     <li>",
"      Use of an antibiotic lock in the infected catheter",
"     </li>",
"     <li>",
"      Leave the infected catheter in place without either replacing the infected catheter or instilling an antibiotic lock in the infected catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal approach to the management of an infected dialysis tunneled cuffed catheter is unclear. In certain settings such as hemodynamic instability due to bacteremia, immediate catheter removal followed by the placement of a temporary non-tunneled catheter for short-term dialysis access is recommended. In other clinical circumstances, different clinical options include tunneled catheter exchange over a guidewire or the use of an antibiotic lock in the existing tunneled catheter. Leaving the infected catheter in place without instilling an antibiotic lock or replacing the infected catheter is NOT recommended.",
"   </p>",
"   <p>",
"    The following sections review some of the data that have evaluated the effectiveness of these approaches. Our specific recommendations concerning the use of these strategies are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Immediate removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immediate removal of the infected cuffed tunneled catheter is generally the best option for achieving cure of the infection, this approach sometimes results in significant subsequent problems in the delivery of dialysis. Nevertheless, severe morbidity and mortality may occur in some patients with certain signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms in whom the infected catheter has not been removed.",
"   </p>",
"   <p>",
"    Thus, when the suspicion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diagnosis of cuffed tunneled dialysis catheter-induced bacteremia is high, we recommend immediately removing the cuffed catheter in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/34,45\">",
"     34,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe sepsis",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Evidence of metastatic infection",
"     </li>",
"     <li>",
"      Signs of accompanying exit-site or tunnel infection, such as pus at the exit-site.",
"     </li>",
"     <li>",
"      If fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacteremia persist 48 to 72 hours after initiation of antibiotics to which the organism is susceptible",
"     </li>",
"     <li>",
"      When infection is due to difficult-to-cure pathogens, such as S. aureus, pseudomonas, Candida, other fungi, or multiply-resistant bacterial pathogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After removal of the tunneled catheter, placement of a temporary non-tunneled catheter is typically the best alternative option for short-term dialysis access. A new, tunneled dialysis catheter can be inserted once blood cultures with negative results are obtained.",
"   </p>",
"   <p>",
"    These issues only apply to tunneled cuffed dialysis catheters. All non-cuffed dialysis catheters should be immediately removed in the presence of bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Guidewire catheter exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed exchange of the infected cuffed catheter over a guidewire with a new catheter two to three days after institution of effective antimicrobial therapy and resolution of fever is a reasonable option for patients who were initially bacteremic, but who lack the above indications for catheter removal or in whom immediate removal of the cuffed catheter is not feasible or practical. This can usually be accomplished before their next dialysis session is due.",
"   </p>",
"   <p>",
"    Thus, if the symptoms that prompted initiation of treatment and the bacteremia resolve within 48 to 72 hours after initiation of systemic antibiotics, the infected catheter can be exchanged over a guidewire with a new catheter. However, blood culture results may not be available within this period of time among patients in some outpatient dialysis units if culture bottles are shipped to a commercial laboratory in a distant location, rather than processed by a local laboratory.",
"   </p>",
"   <p>",
"    In this case, some clinicians may perform catheter exchange over a guidewire in asymptomatic patients prior to confirmation that the bacteremia has resolved. If this is done, we recommend that follow-up blood cultures be obtained after such guidewire-assisted catheter exchanges to verify that the bacteremia has indeed resolved EVEN if the patient remains asymptomatic. If these \"surveillance\" blood cultures return as positive, the tunneled catheter should be removed as cure of infection is unlikely in the face of a documented ongoing bacteremia. As previously mentioned, it is important to realize that bacteremia can be present in patients lacking signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of an ongoing bloodstream infection.",
"   </p>",
"   <p>",
"    Compared with immediate catheter removal, catheter exchange appeared to result in similar cure rates and a decreased rate of required access procedures in some patients in multiple non-randomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/15,19,46-49\">",
"     15,19,46-49",
"    </a>",
"    ]. In most of the preceding studies, patients were selected for exchange only if they met the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Afebrile after 48 hours of antibiotic therapy",
"     </li>",
"     <li>",
"      Clinically stable",
"     </li>",
"     <li>",
"      No evidence of tunnel tract involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the preceding non-randomized studies, roughly 15 to 20 percent of initially enrolled patients required catheter removal within 48 hours; the remainder met criteria for guidewire replacement of the catheter after becoming afebrile with antibiotic therapy. Antibiotic therapy was continued for three weeks. Infection-free catheter survival was observed in more than 90 and 80 percent of patients at 45 and 90 days, respectively. In addition, there was no increase in the frequency of complications. In another study, a high-cure rate (75 percent) was observed even among those with evidence of concurrent exit site infection, provided that a new subcutaneous tunnel was created at the time of the catheter exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, catheter exchange salvage may be effective in highly selected patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/28,47\">",
"     28,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, cuffed catheters should immediately be removed when infection is due to difficult-to-cure pathogens such as S. aureus, pseudomonas, Candida, other fungi, or multiply-resistant bacterial pathogens. These issues and the evidence supporting these statements are discussed separately within UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single retrospective study involving 40 hemodialysis patients with catheter-related candidemia in which guidewire catheter exchange salvage was attempted in patients&rsquo; dialysis catheter-related candidemia concluded that this approach may be beneficial in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/50\">",
"     50",
"    </a>",
"    ]. All patients in this case series received treatment with antifungal medications for two weeks plus either guidewire catheter exchange or catheter removal with delayed replacement. Recurrence of candidemia (approximately 15 percent) and patient survival were similar in both groups. In addition, none of the patients with guidewire catheter exchange had metastatic infection.",
"   </p>",
"   <p>",
"    Nevertheless, unless or until there are more definitive data, we recommend that tunneled catheters be immediately removed in patients with catheter-related candidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antibiotic lock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients without indications for immediate removal of the infected cuffed hemodialysis catheter, the use of an antibiotic lock as adjunctive therapy to systemic antimicrobial administration is an alternative approach to immediate catheter removal with delayed replacement or to guidewire catheter exchange. The goal is to kill the bacteria present in biofilms that frequently adhere to the catheter lumens in hopes of achieving successful treatment of the bacteremia while salvaging the tunneled dialysis catheter. It is important to realize that both an antibiotic lock and systemic antimicrobial therapy are administered with this approach.",
"   </p>",
"   <p>",
"    Catheter lock solutions typically consist of a mixture of an anticoagulant (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or citrate) and high concentrations of an antibiotic in a small volume. This mixture of antibiotic and anticoagulant is then instilled (\"locked\") into each catheter lumen at the end of each dialysis session, in place of standard heparin locks, for the duration of the systemic antibiotic therapy (three weeks). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Lock solutions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following are some types of lock solutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"        Vancomycin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"        ceftazidime",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &mdash; Vancomycin (1 mL of 5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus ceftazidime (0.5 mL of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (0.5 mL of 1,000",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      solution)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"        Vancomycin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &mdash; Vancomycin (1 mL of 5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 1000",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      solution)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"        Ceftazidime",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &mdash; Ceftazidime (1 mL of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 1000",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      solution)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"        Cefazolin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &mdash; Cefazolin (1 mL of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 1000",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      solution)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Antibiotic/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"    </span>",
"    solution should be prepared immediately before instillation into the catheter lumen by mixing the appropriate solutions used for systemic administration of antibiotics in a single syringe. Ideally antibiotic lock solutions should be prepared by pharmacists. However, if this is not feasible in local outpatient settings, such as community-based free-standing dialysis units, nurses who prepare these solutions should be trained in safe injection practices as it relates to use of multidose or single-use vials and instructed in the correct calculation of dosages.",
"   </p>",
"   <p>",
"    If the volume of the catheter lumen is greater than 2 mL, the difference in volume should be made up with additional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Infected catheters should be removed if fever or bacteremia persists despite this approach",
"   </p>",
"   <p>",
"    Antibiotic lock solutions typically consist of the same type of empiric antibiotics as those administered systemically (but obviously different",
"    <span class=\"nowrap\">",
"     amounts/solutions).",
"    </span>",
"    When the systemic antibiotics are switched based upon culture and sensitivity results, the components of the antibiotic lock should also be switched (as listed above). In other words, the antibiotic lock solution is prepared based upon the same antibiotics that are being given systemically. After a therapeutic course of intravenous antibiotics has been completed, antibiotic lock solutions should be discontinued and standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    locks should be resumed.",
"   </p>",
"   <p>",
"    Authors of nine prospective non-randomized studies (four series with hemodialysis catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/28,30,31,51\">",
"     28,30,31,51",
"    </a>",
"    ] and five series with other types of tunneled catheters (chemotherapy or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]) evaluated the efficacy of the use of antibiotic locks in curing bacteremia without removal of tunneled catheter in \"all comers\". Cumulatively, these studies observed a cure in 310 of 405 (76 percent) patients with catheter-related bacteremia.",
"   </p>",
"   <p>",
"    The success rate of an antibiotic lock (in conjunction with systemic antibiotics) in curing catheter-related bacteremia is highly dependent on the infecting organism. For example, the success rate was highest (87 to 100 percent) in patients with Gram-negative infections, 75 to 84 percent for S. epidermidis infections, 61 percent for Enterococcus infections, but only 40 to 55 percent in patients with S. aureus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/16,28,31,54,57\">",
"     16,28,31,54,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no well-designed prospective comparative studies that have examined the efficacy of antibiotic lock therapy versus guidewire catheter exchange. Further study is needed to reconcile the potential benefits of antibiotic lock therapy (such as preservation of the existing catheter) with the potential risks (such as fungal superinfection). Thus, at present, some experts favor the use of guidewire catheter exchange. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some experts prefer using a trial of systemic and antibiotic lock therapy without immediate catheter removal in dialysis patients with blood stream infections (particularly in those with limited vascular access):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the fever persists 48 to 72 hours after initiating of systemic antibiotics and administration of the antibiotic lock solution or bacteremia recurs, the infected catheter should be removed.",
"     </li>",
"     <li>",
"      If fever and bacteremia resolve after initiation of systemic antibiotics and administration of the antibiotic lock solution, the cuffed catheter can be retained. The antibiotic lock is given in conjunction with systemic antibiotic therapy for a total of two to three weeks. The antibiotic lock is renewed after every dialysis session.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      locks are resumed once the course of intravenous antibiotics has been completed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Leaving the catheter in place without intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with dialysis catheter-induced bacteremia, there is NO role for a strategy of leaving the infected catheter in place without either instilling an antibiotic lock or replacing the infected catheter. As mentioned previously, biofilms form rapidly on the inner surface of infected central vein catheters. Although intravenous antibiotics may treat the systemic infection, they cannot eradicate bacteria imbedded in an established biofilm. In other words, intravenous antibiotics alone are insufficient to eradicate most cases of catheter-related bacteremia. Although patients with established biofilms on the surface or the lumens of infected catheters may transiently appear to respond to such intravenous antimicrobial therapy, bacteremia often recurs when such therapy is discontinued. Five large observational studies found that a clinical cure occurred in only 22 to 37 percent of patients whose catheter-related bacteremia was treated with systemic antibiotics alone (without catheter replacement or antibiotic lock) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/15,23,58-60\">",
"     15,23,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With non-dialysis intravascular catheters, a number of measures can be used to help prevent catheter-related infections. Although most of the approaches apply to dialysis catheters, some cannot be used in the dialysis setting because of the chronic need for vascular access, anatomic and blood vessel preservation issues, and other concerns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that the incidence of tunneled dialysis catheter-related infection should be less than 10 and 50 percent at 3 and 12 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/1\">",
"     1",
"    </a>",
"    ]. Our approach to prevention relies upon general measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis units should develop a written protocol describing in detail the proper use of the aseptic technique when vascular access catheters are manipulated and when dressings are applied after dialysis sessions. All personnel should be adequately trained in these techniques and about the importance of routine hand hygiene before and after patient contact.",
"     </li>",
"     <li>",
"      Use of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      gluconate-impregnated sponge (CHGIS) in intravenous catheter dressings may reduce catheter-related infections. We also recommend that nurses or technicians routinely use hand hygiene and wear nonsterile gloves and a mask when dialysis catheters are accessed. The patient should also wear a mask during hookup and disconnection of the catheter and the dialysis tubing. Hand hygiene is necessary before gloves are donned as glove contamination may occur. Moreover, hand hygiene must also follow removal of gloves as hand contamination routinely occurs when contaminated gloves are removed. In addition, we monitor rates of dialysis-associated infections to detect and understand local trends in types of pathogens, incidence and antimicrobial resistance in a manner similar to that described by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple groups have tried to further decrease the risk of catheter infection in hemodialysis patients by using various other methods. These principally involve variations in site care, attempts at elimination of S. aureus nasal carriage, the use of different types of dialysis catheters, and the topical application of different substances.",
"   </p>",
"   <p>",
"    We currently do NOT utilize the antibiotic-lock technique, or catheters impregnated with antimicrobial agents on a systematic basis in our dialysis units. Some, but not all, experts favor the use of topical antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Topical antimicrobial exit site application",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to help prevent dialysis catheter-induced bacteremia has been the topical use of povidone-iodine, Polysporin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other agents at catheter entrance sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. Topical antibiotic use appears to decrease the rate of bacteremia significantly. This was best shown in a meta-analysis, which found that topical antibiotics, compared with no antibiotic therapy, lowered the bacteremia rate (rate ratio 0.22, 95% CI 0.12-0.40), exit-site infection rate (0.17, 95% CI 0.08-0.38), requirement for catheter removal, and hospitalization for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are two significant problems with this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A substantial percentage of healthcare-associated staphylococcal infections are now due to community-acquired strains of methicillin-resistant S. aureus in which nasal colonization is uncommon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The emergence of either low- or high-level resistance to topical or intraluminal antimicrobial agents is a definite and predictable risk of such therapies. Emergence of resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      , for example, is an increasing problem in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Data suggest that widespread use of mupirocin in Canada is associated with the emergence of a plasmid-encoded gene (mupA) that results in high-level resistance to this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/70\">",
"       70",
"      </a>",
"      ]. One study in which topical mupirocin was used routinely to prevent S. aureus exit site infections in patients on chronic peritoneal dialysis reported that 15 percent of S. aureus isolates became resistant to mupirocin at the end of the four year study period (these isolates were identified in 3 percent of all patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these risks, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    antiseptic ointment or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"      bacitracin",
"     </a>",
"     /gramicidin/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"      polymyxin B",
"     </a>",
"    </span>",
"    ointment at the exit site after catheter insertion and at the end of each hemodialysis session is strongly recommended by a joint working group led by the Society of Critical Care Medicine and the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Catheters with a lower infection rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodialysis catheter has evolved from a single lumen catheter to a tunneled, cuffed device designed to decrease infection and permit longer usage. Subsequent efforts have been focused on designing catheters with a lower infection rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/65,73-75\">",
"     65,73-75",
"    </a>",
"    ]. A 2009 systematic review that evaluated 29 trials with 2886 patients and 3005 catheters found NO significant decrease in catheter related bacteremia and exit-site infections with antimicrobial coating of hemodialysis catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the possible contamination of catheters with skin flora, subcutaneous ports that provide long-term access to the circulation have also been developed in the attempt to prevent infection. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Lock solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filling the catheter with antimicrobial agents has been used to help prevent dialysis catheter infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/65,76-85\">",
"     65,76-85",
"    </a>",
"    ]. A 2009 systematic review evaluated 29 trials with 2886 patients and 3005 catheters found that antimicrobial locks were associated with decreased rates of catheter related bacteremia (rate ratio 0.33, 95% CI 0.24-0.45) and exit-site infections (rate ratio 0.67, 95% CI 0.47-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, a number of issues remain concerning the use of this method for prevention of catheter-related infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged use of any antimicrobial agents (eg, greater than 6 to 12 months) is likely to result in the development of antibiotic-resistant organisms, the findings of the above meta-analysis notwithstanding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/84\">",
"       84",
"      </a>",
"      ]. In one observational study in which",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      was routinely instilled at the end of dialysis, although the total catheter-related infection rate decreased, gentamicin-resistant infections increased beginning six months after initiation of the protocol, resulting in four deaths, two cases of septic shock, and four cases of endocarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic toxicity may result from leakage of these solutions. In particular,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      locks have been associated with ototoxicity in 10 percent of patients in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/76\">",
"       76",
"      </a>",
"      ]. Concentrated citrate locks can potentially cause life-threatening hypocalcemia and intolerable side effects (such as metallic taste or facial or digital paresthesias) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States, current reimbursement schemes do not provide payment for these agents, thereby placing a financial burden on dialysis units. In addition, such agents are not yet approved by the FDA for this indication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems associated with the development of antibiotic-resistant organisms may be addressed in part by using antibiotics that are not commonly used to treat serious infections. As an example, one randomized open-label trial that included 204 incident tunneled and nontunneled catheters demonstrated a reduction in overall catheter-related bacteremia associated with the use of a lock solution that contained",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and EDTA compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (4.3 versus 1.1 per 1000 catheter-days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, among 52 tunneled catheters that were included in the trial, although fewer episodes of bacteremia occurred in catheters instilled with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    -EDTA compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (1.8 versus 4.8 per 1000 catheter-days, respectively) this difference was not significant.",
"   </p>",
"   <p>",
"    We continue to advise against the use of antibiotic-lock solutions for prevention of catheter-induced bacteremia. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Antibiotic lock'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Elimination of S. aureus nasal carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy to decrease nasal carriage of S. aureus has led to fewer access-related infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/8/29834/abstract/90\">",
"     90",
"    </a>",
"    ]. This finding suggests that a large number of S. aureus dialysis infections are related in part to a high rate of nasal carriage. However, the emergence of resistance with chronic antibiotic use has limited the widespread adoption of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central venous catheters have become an acceptable form of permanent vascular access. Both non-tunneled, non-cuffed catheters and tunneled, cuffed catheters are available. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of bacteremias in hemodialysis patients are caused by infection of vascular catheters. Dialysis catheter-related bacteremia may also be associated with metastatic complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram-positive organisms are responsible for most dialysis catheter-related infections. Coagulase-negative staphylococcal and S. aureus together account for 40 to 80 percent of cases, while the remainder is due predominantly to enterococci and Gram-negative rods. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although nonspecific, fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chills are the most sensitive clinical manifestations of catheter-induced bacteremia. With suspected bacteremia, two blood cultures should be drawn, which can consist of a single peripheral drawn blood sample and a second sample obtained from the dialysis catheter or two samples drawn from separate peripheral sites. However, if blood cannot be obtained from a peripheral vein, two separate samples drawn 10 to 15 minutes apart from the dialysis catheter or dialysis tubing should be obtained. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical Manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive diagnosis of dialysis catheter-induced bacteremia requires one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Concurrent positive blood cultures of the same organism from the catheter and a peripheral vein.",
"     </li>",
"     <li>",
"      Culture of the same organism from both the catheter tip and at least one percutaneous blood culture.",
"     </li>",
"     <li>",
"      Cultures of the same organism from two peripherally drawn blood cultures and an absence of an alternate focus of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a peripheral blood sample cannot be obtained, catheter-induced bacteremia can be diagnosed if TWO cultures drawn at separate times (10 to 15 minutes) from blood tubing are positive with a credible pathogen in a patient with sign and symptoms of bacteremia, but without evidence of an alternate source of infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that empiric systemic antimicrobial therapy be administered to all dialysis patients suspected of having dialysis catheter-induced bacteremia. Broad spectrum coverage should consist of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      may be substituted for vancomycin if the patient has a documented vancomycin allergy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the organism and sensitivity have been identified, the antibiotic regimen should be modified accordingly.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      should be used for patients who have catheter-related methicillin-sensitive S. aureus bacteremia. (See",
"      <a class=\"local\" href=\"#H89483369\">",
"       'Methicillin-sensitive staphylococcus'",
"      </a>",
"      above.) The optimal duration of antimicrobial therapy remains uncertain. The length of therapy depends upon the infecting organism, presence of metastatic infection, and response to therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tailored treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with positive blood cultures, repeat blood cultures should be obtained 48 to 96 hours after the institution of treatment. If these repeat blood cultures remain positive, catheter removal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      additional evaluation for a metastatic infection or endocarditis may be necessary. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Catheter management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All non-cuffed catheters should be removed in the presence of bacteremia.",
"     </li>",
"     <li>",
"      With the",
"      <span class=\"nowrap\">",
"       suspicion/diagnosis",
"      </span>",
"      of catheter-induced bacteremia, we recommend immediately removing the cuffed catheter in the following circumstances (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe sepsis",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Evidence of metastatic infection",
"     </li>",
"     <li>",
"      Signs of accompanying exit-site or tunnel infection, such as pus at the exit-site.",
"     </li>",
"     <li>",
"      If fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacteremia persist 48 to 72 hours after initiation of antibiotics to which the organism is susceptible.",
"     </li>",
"     <li>",
"      When infection is due to difficult-to-cure pathogens such as S. aureus, pseudomonas, candida, other fungi, or multiply-resistant bacterial pathogens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Immediate removal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In this setting, a temporary non-tunneled non-cuffed catheter is placed for short-term dialysis access. A new, tunneled dialysis catheter is inserted once bacteremia has resolved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with bacteremia due to S. aureus, Pseudomonas, or Candida infection and with other access options, we recommend immediate removal of the cuffed catheter and placement of a temporary catheter into another site (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If there are absolutely NO alternative sites for catheter insertion, catheter exchange over a guidewire can be performed.",
"     </li>",
"     <li>",
"      Among patients without indications for immediate removal of the cuffed catheter, the principal options are guidewire catheter exchange or instillation of an antibiotic lock solution. We suggest the use of guidewire exchange rather than the antibiotic lock solution (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If fever or bacteremia persists 48 to 72 hours after initiation of systemic antibiotics, the cuffed catheter should be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the symptoms that prompted initiation of treatment and bacteremia resolve within 48 to 72 hours after initiation of systemic antibiotics, the infected catheter can be exchanged over a guidewire with a new catheter. However, due to practical concerns, some clinicians will perform catheter exchange over a guidewire in asymptomatic patients prior to confirmation that the bacteremia has resolved. If this is done, we recommend that follow-up blood cultures be obtained to verify that the bacteremia has resolved even if the patient remains asymptomatic. The tunneled catheter should be removed in the setting of confirmed bacteremia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Guidewire catheter exchange'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, among patients without indications for immediate removal of the cuffed catheter, some experts instill an antibiotic lock solution as adjunctive therapy to systemic antimicrobial treatment rather than guidewire catheter exchange:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If fever, bacteremia, or hemodynamic instability persists 48 to 72 hours after initiation of systemic antibiotics and administration of the antibiotic lock solution, the cuffed catheter should be removed.",
"     </li>",
"     <li>",
"      If fever and bacteremia resolve after initiation of systemic antibiotics and administration of the antibiotic lock solution, the cuffed catheter can be retained. The antibiotic lock is given in conjunction with systemic antibiotic therapy for a total of two to three weeks. The antibiotic lock is renewed after every dialysis session.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      locks are renewed once the course of systemic antibiotics has been completed.",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antibiotic lock'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the catheter is removed, patients who remain febrile or have positive cultures should undergo a thorough examination for metastatic complications (such as endocarditis and vertebral osteomyelitis). Clinical signs of metastatic infection may also occur in patients without such signs or symptoms. Thus, all patients with catheter-associated bacteremia should be carefully assessed by serial clinical exams.",
"     </li>",
"     <li>",
"      Although most of the approaches with non-dialysis catheters apply to dialysis catheters, some preventive measures cannot be used in the dialysis setting because of the chronic need for vascular access, anatomic and blood vessel preservation issues, and other concerns. Our approach to prevention relies upon general measures. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/1\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/2\">",
"      Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 2005; 46:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/3\">",
"      Danese MD, Griffiths RI, Dylan M, et al. Mortality differences among organisms causing septicemia in hemodialysis patients. Hemodial Int 2006; 10:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/4\">",
"      Nissenson AR, Dylan ML, Griffiths RI, et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 2005; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/5\">",
"      Inrig JK, Reed SD, Szczech LA, et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clin J Am Soc Nephrol 2006; 1:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/6\">",
"      Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/7\">",
"      Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/8\">",
"      Taylor G, Gravel D, Johnston L, et al. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control 2004; 32:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/9\">",
"      Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/10\">",
"      Allon M, Daugirdas J, Depner TA, et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 2006; 47:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/11\">",
"      Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004; 44:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/12\">",
"      Stevenson KB, Hannah EL, Lowder CA, et al. Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 2002; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/13\">",
"      Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant 2004; 19:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/14\">",
"      Kovalik EC, Raymond JR, Albers FJ, et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. J Am Soc Nephrol 1996; 7:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/15\">",
"      Marr KA, Sexton DJ, Conlon PJ, et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/16\">",
"      Maya ID, Carlton D, Estrada E, Allon M. Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2007; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/17\">",
"      Kozeny GA, Venezio FR, Bansal VK, et al. Incidence of subclavian dialysis catheter-related infections. Arch Intern Med 1984; 144:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/18\">",
"      Teehan GS, Bahdouch D, Ruthazer R, et al. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/19\">",
"      Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int 2000; 57:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/20\">",
"      Mitchell D, Krishnasami Z, Allon M. Catheter-related bacteraemia in haemodialysis patients with HIV infection. Nephrol Dial Transplant 2006; 21:3185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/21\">",
"      Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/22\">",
"      Cheesbrough JS, Finch RG, Burden RP. A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 1986; 154:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/23\">",
"      Swartz RD, Messana JM, Boyer CJ, et al. Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J Am Soc Nephrol 1994; 4:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/24\">",
"      Almirall J, Gonzalez J, Rello J, et al. Infection of hemodialysis catheters: incidence and mechanisms. Am J Nephrol 1989; 9:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/25\">",
"      Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients--United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/27\">",
"      Dryden MS, Samson A, Ludlam HA, et al. Infective complications associated with the use of the Quinton 'Permcath' for long-term central vascular access in haemodialysis. J Hosp Infect 1991; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/28\">",
"      Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant 2004; 19:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/29\">",
"      Mokrzycki MH, Schr&ouml;ppel B, von Gersdorff G, et al. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol 2000; 11:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/30\">",
"      Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/31\">",
"      Vardhan A, Davies J, Daryanani I, et al. Treatment of haemodialysis catheter-related infections. Nephrol Dial Transplant 2002; 17:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/32\">",
"      Sychev D, Maya ID, Allon M. Clinical management of dialysis catheter-related bacteremia with concurrent exit-site infection. Semin Dial 2011; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/33\">",
"      Allon M. Treatment guidelines for dialysis catheter-related bacteremia: an update. Am J Kidney Dis 2009; 54:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/34\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/35\">",
"      Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/36\">",
"      Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/37\">",
"      Taylor ME, Allon M. Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience. Am J Kidney Dis 2010; 55:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/38\">",
"      Salama, NN, Segal, JH, Churchwell, MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. CJASN 2009; 4:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/39\">",
"      Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/40\">",
"      Tokars JI. Vancomycin use and antimicrobial resistance in hemodialysis centers. Am J Kidney Dis 1998; 32:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/41\">",
"      Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis 1998; 32:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/42\">",
"      Fogel MA, Nussbaum PB, Feintzeig ID, et al. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis 1998; 32:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/43\">",
"      Chan KE, Warren HS, Thadhani RI, et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/44\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/45\">",
"      Rijnders BJ, Peetermans WE, Verwaest C, et al. Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: a randomized trial. Intensive Care Med 2004; 30:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/46\">",
"      Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/47\">",
"      Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int 1998; 53:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/48\">",
"      Beathard GA, Litchfield T, Physician Operators Forum of RMS Lifeline, Inc. Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. Kidney Int 2004; 66:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/49\">",
"      Ashby DR, Power A, Singh S, et al. Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc Nephrol 2009; 4:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/50\">",
"      Sychev D, Maya ID, Allon M. Clinical outcomes of dialysis catheter-related candidemia in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/51\">",
"      Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/52\">",
"      Atkinson JB, Chamberlin K, Boody BA. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. J Pediatr Surg 1998; 33:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/53\">",
"      Boorgu R, Dubrow AJ, Levin NW, et al. Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. ASAIO J 2000; 46:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/54\">",
"      Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/55\">",
"      Messing, B, Peitra-Cohen, S, Debure, A, et al. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. J Parenteral &amp; Enteral Nutrition 1988; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/56\">",
"      Panagea S, Galloway A. Intravascular-catheter-related infections. Lancet 1998; 351:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/57\">",
"      Peterson WJ, Maya ID, Carlton D, et al. Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2009; 53:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/58\">",
"      Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/59\">",
"      Lund GB, Trerotola SO, Scheel PF Jr, et al. Outcome of tunneled hemodialysis catheters placed by radiologists. Radiology 1996; 198:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/60\">",
"      Pourchez T, Morini&egrave;re P, Fournier A, Pietri J. Use of Permcath (Quinton) catheter in uraemic patients in whom the creation of conventional vascular access for haemodialysis is difficult. Nephron 1989; 53:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/61\">",
"      Saad TF. Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001; 14:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/62\">",
"      Lok CE, Stanley KE, Hux JE, et al. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/63\">",
"      Johnson DW, van Eps C, Mudge DW, et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 2005; 16:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/64\">",
"      James MT, Conley J, Tonelli M, et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008; 148:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/65\">",
"      Rabindranath KS, Bansal T, Adams J, et al. Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections. Nephrol Dial Transplant 2009; 24:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/66\">",
"      McCann M, Moore ZE. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database Syst Rev 2010; :CD006894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/67\">",
"      Battistella M, Bhola C, Lok CE. Long-term follow-up of the Hemodialysis Infection Prevention with Polysporin Ointment (HIPPO) Study: a quality improvement report. Am J Kidney Dis 2011; 57:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/68\">",
"      Farr BM. Mupirocin to prevent S. aureus infections. N Engl J Med 2002; 346:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/69\">",
"      Deshpande LM, Fix AM, Pfaller MA, et al. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002; 42:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/70\">",
"      Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007; 51:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/71\">",
"      Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/72\">",
"      O'Grady NP, Alexander M, Burns LA, et al. Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin Infect Dis 2011; 52:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/73\">",
"      Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA 1991; 265:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/74\">",
"      Dahlberg PJ, Agger WA, Singer JR, et al. Subclavian hemodialysis catheter infections: a prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections. Infect Control Hosp Epidemiol 1995; 16:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/75\">",
"      Jain G, Allon M, Saddekni S, et al. Does heparin coating improve patency or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol 2009; 4:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/76\">",
"      Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/77\">",
"      McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004; 66:801.",
"     </a>",
"    </li>",
"    <li>",
"     McIntyre, C, 2005, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/79\">",
"      Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/80\">",
"      Panhotra BR, Al-Arabi Al-Ghamdi AM, Saxena AK. Antibiotic-Heparin Lock Technique: A Potentially Precious Tool to Prevent Hemodialysis Catheter-related Septicemia. Saudi J Kidney Dis Transpl 2004; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/81\">",
"      Saxena AK, Panhotra BR, Sundaram DS, et al. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int 2006; 70:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/82\">",
"      Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 2006; 48:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/83\">",
"      Bleyer AJ. Use of antimicrobial catheter lock solutions to prevent catheter-related bacteremia. Clin J Am Soc Nephrol 2007; 2:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/84\">",
"      Jaffer Y, Selby NM, Taal MW, et al. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis 2008; 51:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/85\">",
"      Moran J, Sun S, Khababa I, et al. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. Am J Kidney Dis 2012; 59:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/86\">",
"      Allon M. Prophylaxis against dialysis catheter-related bacteremia: a glimmer of hope. Am J Kidney Dis 2008; 51:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/87\">",
"      Landry DL, Braden GL, Gobeille SL, et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/88\">",
"      Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis 2009; 53:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/89\">",
"      Campos RP, do Nascimento MM, Chula DC, Riella MC. Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. J Am Soc Nephrol 2011; 22:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/8/29834/abstract/90\">",
"      Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315:91.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1966 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29834=[""].join("\n");
var outline_f29_8_29834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Metastatic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic difficulties among dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Empiric treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tailored treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89483362\">",
"      Methicillin-resistant staphylococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89483369\">",
"      Methicillin-sensitive staphylococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89483383\">",
"      Vancomycin-resistant enterococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89483397\">",
"      Gram-negative organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89483390\">",
"      Candidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Monitoring issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Catheter management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Immediate removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Guidewire catheter exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antibiotic lock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Leaving the catheter in place without intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Topical antimicrobial exit site application",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Catheters with a lower infection rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Lock solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Elimination of S. aureus nasal carriage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Catheter management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_8_29835="Available endoclips";
var content_f29_8_29835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Available endoclips",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Open clip size, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minimum endoscope channel size, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Special characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Olympus",
"       </td>",
"       <td>",
"        QuickClip2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        Rotatable. Available in 165 cm and 230 cm lengths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QuickClip2Long",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        Rotatable. Available in 165 cm and 230 cm lengths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Resolution",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        Jaws can be re-opened to reposition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Cook Medical",
"       </td>",
"       <td>",
"        TriClip",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TriClip",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        Integrated flush port.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M. Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29835=[""].join("\n");
var outline_f29_8_29835=null;
var title_f29_8_29836="Canaliculoocular reflexes";
var content_f29_8_29836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The canaliculoocular reflexes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Canal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred head motion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Eye muscles excited",
"       </td>",
"       <td class=\"subtitle1\">",
"        Resulting eye motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right horizontal",
"       </td>",
"       <td>",
"        Right turn",
"       </td>",
"       <td>",
"        <p>",
"         Left lateral rectus",
"        </p>",
"        <p>",
"         Right medial rectus",
"        </p>",
"       </td>",
"       <td>",
"        Leftward",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right anterior",
"       </td>",
"       <td>",
"        <p>",
"         Neck flexion",
"        </p>",
"        <p>",
"         Right head tilt",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Right superior rectus",
"        </p>",
"        <p>",
"         Left inferior oblique",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Elevation (right gaze)",
"        </p>",
"        <p>",
"         Counterclockwise torsion (left gaze)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right posterior",
"       </td>",
"       <td>",
"        <p>",
"         Neck extension",
"        </p>",
"        <p>",
"         Right head tilt",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Left inferior rectus",
"        </p>",
"        <p>",
"         Right superior oblique",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Depression (left gaze)",
"        </p>",
"        <p>",
"         Counterclockwise torsion (right gaze)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left horizontal",
"       </td>",
"       <td>",
"        Left turn",
"       </td>",
"       <td>",
"        <p>",
"         Right lateral rectus",
"        </p>",
"        <p>",
"         Left medial rectus",
"        </p>",
"       </td>",
"       <td>",
"        Rightward",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left anterior",
"       </td>",
"       <td>",
"        <p>",
"         Neck flexion",
"        </p>",
"        <p>",
"         Left head tilt",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Left superior rectus",
"        </p>",
"        <p>",
"         Right inferior oblique",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Elevation (left gaze)",
"        </p>",
"        <p>",
"         Clockwise torsion (right gaze)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left posterior",
"       </td>",
"       <td>",
"        <p>",
"         Neck extension",
"        </p>",
"        <p>",
"         Left head tilt",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Right inferior rectus",
"        </p>",
"        <p>",
"         Left superior oblique",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Depression (right gaze)",
"        </p>",
"        <p>",
"         Clockwise torsion (left gaze)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Head and eye rotations are described from the point of view of the patient. As examples, a right head tilt is a clockwise rotation of the head; counterclockwise torsion of the eyes means that the superior pole of the eyes are tilted to the left.",
"    <div class=\"footnotes\">",
"     Right gaze: maximally in right gaze; left gaze: maximally in left gaze.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29836=[""].join("\n");
var outline_f29_8_29836=null;
var title_f29_8_29837="Contents: Complementary medicine";
var content_f29_8_29837=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Complementary medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Complementary medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/50/28457\">",
"           Acupuncture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/63/23542\">",
"           Clinical use of echinacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/28/11720\">",
"           Clinical use of ginkgo biloba",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/18/33061\">",
"           Clinical use of saw palmetto",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/8/27784\">",
"           Clinical use of St. John's wort",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/17/26903\">",
"           Homeopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/4/20554\">",
"           Overview of herbal medicine and dietary supplements",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CAB2786BA2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f29_8_29837=[""].join("\n");
var outline_f29_8_29837=null;
var title_f29_8_29838="Drug and toxin related pulse changes";
var content_f29_8_29838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced changes in blood pressure and pulse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypertension with tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pseudoephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs (early)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines (some)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiparkinson agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clozapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Central hallucinogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Designer amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lysergic acid diethylamide (LSD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phencyclidine (PCP)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Synthetic cannabinoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Envenomations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Black widow spider bite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scorpion stings",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            MAOIs (foods with tyramine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergic agents (sometimes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid hormone",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypertension with bradycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Alpha-adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylpropanolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylephrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phentermine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ergot alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sumatriptan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clonidine (early)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Guanfacine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Imidazolines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tetrahydrozoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oxymetazoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Steroid hormones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mineralocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Estrogen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Progesterone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Androgens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yohimbine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lead",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disulfiram reaction (early)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypotension with tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Beta-adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Isoproterenol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Terbutaline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disulfiram reaction (late)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Toxic alcohols",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Isopropyl alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Alpha-adrenergic antagonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydralazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals (acute)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Iron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colchicine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sodium nitroprusside",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypotension with bradycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium-channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cardiac glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digitalis purpurea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oleander",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Red squill",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bufotenin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alpha-methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide (late)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiarrhythmics",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29838=[""].join("\n");
var outline_f29_8_29838=null;
var title_f29_8_29839="Dislocated tooth PI";
var content_f29_8_29839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Avulsed incisors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Permanent teeth that are knocked out should be handled carefuly on the top (crown, see arrows) to avoid damaging them.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis J McTigue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_8_29839=[""].join("\n");
var outline_f29_8_29839=null;
